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Abstract
Human regulatory T lymphocytes (Tregs) are a subset of CD4+ T cells that inhibit
other T cells by producing TGF-β1, an immunosuppressive cytokine. All T cells
produce TGF-β1 as an inactive precursor, but only Tregs are able to activate
the cytokine. Activation of TGF-β1 requires binding of the precursor to GARP, a
Treg membrane protein. Forced expression of GARP in other T cells (Th) is not
sufficient to activate TGF-β1. We thus searched for proteins expressed in Tregs,
and not in Th, that interact with GARP and contribute to TGF-β1 activation in these
cells. First, we screened a Treg cDNA library by yeast two-hybrid using GARP
as bait. We identified LAPTM4B, a membrane protein expressed at higher levels
in Tregs than in Th cells. We showed that LAPTM4B is a negative regulator of
TGF-β1 production in Tregs but is not involved in TGF-β1 activation. Second, we
immunoprecipitated GARP in Treg lysates and identified 7 co-immunoprecipitated
proteins by Mass Spectrometry. Four are n...
Document type : Thèse (Dissertation)
Référence bibliographique
Huygens, Caroline. Identification of proteins regulating TGF-ß1 production in human regulatory T
lymphocytes.  Prom. : Lucas, Sophie


! ! ! ! ! ! !        ! !       
! ! ! ! ! ! ! !     
Identification of proteins 
regulating TGF-β1 production 
in human regulatory T lymphocytes 
Caroline Huygens
Février 2015
Thèse présentée en vue de l’obtention du grade 
de docteur en Sciences Biomédicales et Pharmaceutiques
Secteur des sciences de la santé

Président du jury
Prof. Thomas Michiels
de Duve Institute
Université catholique de Louvain
Membres du jury
Dr. Sabine Bailly
CEA Grenoble
Unité INSERM U1036/BCI
Prof. Olivier Feron
Pole of Pharmacology and Therapeutics
Institute of Experimental and Clinical Research
Université catholique de Louvain
Prof. Stefan Constantinescu
Ludwig Institute for Cancer Research
de Duve Institute
Université catholique de Louvain
Prof. Pierre Coulie
de Duve Institute
Université catholique de Louvain
Promoteur
Prof. Sophie Lucas
de Duve Institute
Université catholique de Louvain

Je souhaite tout d’abord remercier ma promotrice pour ces 5 années passées dans son équipe. 
Merci Sophie d’avoir pris le temps de me transmettre tes connaissances, d’avoir eu confiance en 
moi et de m’avoir toujours poussée à aller plus loin!  Je garderai un très bon souvenir de ma thèse, 
j’ai énormément appris et j’espère qu’on continuera à se voir! Merci aussi pour ton soutien dans 
tous les projets dans lesquels je me suis investie en dehors du labo!
Je tiens également à remercier l’ensemble de mon jury de thèse pour son soutien tout au long de 
mon parcours.  Vous m’avez encouragé à persévérer malgré les embûches de ce projet, et s’il a 
abouti c’est aussi grâce à vous!  J’adresse également un remerciement particulier à Pierre Coulie 
et à tout le corps enseignant du cours d’immunologie de m’avoir transmis le goût de l’immunologie 
et de la démarche scientifique.  
Mes remerciements vont ensuite à l’équipe que j’ai côtoyée, chanceuse que je suis, au cours de ces 
années et qui sont devenus bien plus que des collègues! Julie, merci de m’avoir accueillie à bras 
ouverts dès mon arrivée au labo! Merci pour ta disponibilité, pour ton aide au quotidien ainsi que 
pour la relecture de ce manuscrit! Olivier, merci pour ta générosité et pour ton aide! Nos échanges 
scientifiques, idéologiques et politiques pendant que nous cultivions nos cellules vont me manquer! 
Stéphanie L. merci à toi d’avoir participé avec énergie au projet LAPTM4B pendant ton mémoire! 
Ton enthousiasme a fait énormément de bien à ce travail! Merci aussi à Stéphanie D. pour sa 
participation à ce projet.  Ce fut un plaisir de travailler avec toi! Merci également à toi Maria pour 
l’aide considérable que tu apportes à notre travail au quotidien! Merci aussi pour ta bonne 
humeur! Julia, merci pour nos discussions scientifiques ou non autour d’un bon café! Merci à toi 
Emilie d’avoir contribué à ce projet et à toi Axelle de me faire rire aux éclats! Je souhaite à 
Stéphanie L., Olivier et Sara une excellente suite et fin de thèse! Bon courage et bonne chance!
Je souhaite également remercier les différents groupes avec lesquels nous partageons le 3è étage. 
D’abord, l’équipe de Pierre Coulie pour leur aide et leur amitié.  Merci à Nicolas, Nathalie R., 
Tiphanie, Orian, Charlotte, David, Gérald et à Téofila. Un merci tout particulier à Catherine et à 
Suzanne pour leur gentillesse et leur aide précieuse durant ces années! J’adresse également mes 
remerciements au groupe d’Etienne De Plaen! Merci vous Etienne pour vos conseils pour les 
cultures de levures! Merci à vous Marc, Juliette, et Nathalie pour votre aide lors de mes recherches 
de divers produits chimiques et merci aussi pour toutes nos conversations (rarement) scientifiques! 
Merci aussi à Marjorie, Aurélie, Marie-Sophie, Luc, Délia, Alexandre, Nathalie V., Rui, Aline, 
Florence, Joanna, Wenbin et Céline pour la bonne ambiance au travail et au traminot le vendredi 
soir! Merci aussi à toute l’équipe technique de l’Institut Ludwig qui nous permet de travailler dans 
des conditions idéales!
J’aimerais également remercier tous les membres de l’Institut de Duve et de l’Institut Ludwig. 
Chaque rencontre et collaboration a été bénéfique pour mon projet! Je pense particulièrement à 
Donatienne, Antoine, Vitalina, Anabelle, Sandrine,... Nous avons la chance de travailler dans un 
environnement qui favorise les échanges d’idées, de protocoles et de produits! Ce fut un honneur de 
travailler à l’Institut imaginé par Christian de Duve. 
Ensuite je voudrais remercier mes amis qui ont été présents et m’ont soutenue tout au long de ma 
thèse. D’abord les SBIMs! Merci pour vos encouragements Jess, Nath (il fallait au moins te citer 
deux fois dans mes remerciements!), Val, Alex, Berny, Antoine, Fab, Laura, Auré et Lorraine! Ca a 
été un plaisir de partager les auditoires et l’expérience de la thèse avec vous! Je sais que nous 
continuerons à nous voir!  Merci à ma nouvelle bande de copines : Franci, Violetta, Eva et Maria! 
Vous êtes devenues pour moi, plus que des collègues ou des partenaires de hockey, j’adore discuter 
avec vous et préparer notre monde de demain! Merci à toute l’équipe de dames 3 du LLNHC, 
anciennement les cougars maintenant devenues les zébras, vous avez été ma bouffée d’oxygène 
pendant ma thèse! A très vite sur le terrain ou au bar pour discuter tactique!  Merci à mes amis de 
looongue date Perrine, Arabelle, Séverine, Dé, Jul, Cel, Anne-so, Emi, Mike, Den, Jem, Bibo...! 
Vous citer tous ici serait impossible mais merci à tous pour votre amitié de ces 20 dernières années, 
et pour vos messages d’encouragements lors de la rédaction du manuscrit et lors de ma défense! 
Ca y est, on peut le boire ce champagne! Merci enfin à JAVVA et à tous ses membres de m’avoir 
offert la possibilité de prendre du recul pendant ma thèse, de m’avoir enrichi et de contribuer à 
rendre le monde meilleur!  
Finalement, je remercie toute ma famille d’avoir été à mes côtés pendant ces années! Mes parents 
qui m’ont offert la possibilité d’arriver là aujourd’hui et qui m’ont soutenue dans les moments 
joyeux ou difficiles toute ma vie! Merci à mes soeurs d’être des personnes humaines et joyeuses! Ne 
changez surtout pas! Merci aussi à toi Mamy pour ton soutien et ton enthousiasme! Merci pour 
tout!
Je dédie cette thèse à mon Bon-Papa.

Table of contents
Abbreviations 13
Summary 15
Introduction 17
1. Regulatory T lymphocytes and cancer 18
1.1. Cancer immunotherapy 18
1.2. Regulatory T cells 19
1.3. Tregs in cancer 22
1.4. Mechanisms of immunosuppression by murine and human Tregs 23
2. TGF-β1, an immunosuppressive cytokine 26
2.1. TGF-β1 synthesis, processing and activation 26
2.3. TGF-β signal transduction 31
2.4. TGF-β functions in the immune system 33
2.4.1. TGF-β production by T cells 34
2.4.2. T cells as targets of TGF-β in the immune system 35
2.4.3. Other roles of TGF-β in T cell differentiation and function 36
3. GARP, a transmembrane protein expressed by activated human Tregs 39
3.1. Structure of GARP (or LRRC32) 39
3.2. GARP expression pattern and regulation 40
3.3. Functions of GARP in Tregs 40
4. How to study protein-protein interactions? 45
4.1 PPI detection by «in-cell» methods 46
4.1.1 Yeast Two-Hybrid systems 46
4.1.2 Mammalian Two-Hybrid systems 56
4.1.3 Proximity Ligation Assay 62
4.2 PPI detection by biochemical methods 64
4.2.1. Co-immunoprecipitation and co-Affinity Purification 64
4.2.2. Luminescence-based mammalian interactome mapping 67
4.2.3. Overlay or Far Western 68
4.2.4. Phage Display  69
4.3  The Interactome 71
Aim of the study 73
Results 75
1. LAPTM4B interacts with GARP and decreases TGF-β1 production in human 
regulatory T cells  76
2. Identification of proteins interacting with GARP in human Tregs by 
immunoprecipitation followed by mass spectrometry 97
Discussion and Perspectives 111
1. Two distinct approaches to identify GARP partners in human Tregs 112
2. Seven candidates identified by IP-MS 116
3. LAPTM4B, a candidate identified by MYTH 118
3.1. Regulation of LAPTM4B expression 118
3.2. Roles of LAPTM4B in human Tregs 119
3.3 Other described functions of LAPTM4B, and LAPTM family members 119
3.4. LAPTM4B in Treg suppressive function 121
4.  TGF-β activators in Tregs 123
References 125
Abbreviations
5-FOA  5-Fluoroorotic Acid
A2AR  Adenosine A2A Receptor
AD  Activating Domain
AP  Affinity Purification
BiFC  Bimolecular Fluorescence Complementation
BMP  Bone Morphogenetic Protein
BRET  Bioluminesence Resonance Energy Transfer 
cAMP  cyclic Adenosine Monophosphate
CD  Cluster of Differentiation
cDNA  complementary DeoxyriboNucleic Acid
CpG  Cytosine Guanine dinucleotide
co-IP  co-ImmunoPrecipitation
co-SMAD common SMAD
CTL  Cytotoxic T Lymphocyte
CTLA4  Cytotoxic T Lymphocyte-associated Antigen 4
Cys  Cysteine
DC  Dendritic Cell
DBD  DNA Binding Domain
dn  dominant negative
DNA  DeoxyriboNucleic Acid
ER  Endoplasmic Reticulum
FACS  Fluorescence-Activated Cell Sorting
FDA  Food and Drug Administration
FOXP3  Forkhead box P3 
FRET  Fluoresence Resonance Energy Transfer
GAP  GTPase-activating protein
GARP  Glycoprotein A Repetition Predominant
GDF  Growth and Differentiation Factor
GEF  Guanine nucleotide Exchanging Factor
GFP  Green Fluorescent Protein
GST  Glutathione S-Transferase
GTP  Guanosine TriPhosphate
GVHD  Graft Versus Host Disease
IDO  Indoleamine 2,3-dioxygenase
IL  Interleukin
IPEX  Immune dysregulation Polyendocrinopathy Enteropathy X-linked syndrome
I-SMAD inhibitory SMAD
iTreg  induced Treg
JAK  Janus Kinase
KO  Knock Out
LAP  Latency-Associated Peptide
LAPTM4B Lysosomal-Associated Protein Transmembrane 4B
LRRC32 Leucine Rich Repeat Containing Protein 32
LTBP  Latent TGF-β Binding Protein
M2H  Mammalian two-Hybrid
mAbs  monoclonal Antibodies
MAGE  Melanoma Antigen-encoding Gene
MAPPIT  Mammalian Protein-Protein Interaction Trap
mRNA  messenger RNA
MS  Mass Spectrometry
13
MS-qPCR Methylation-Specific qPCR
MYTH  Membrane Yeast Two-Hybrid
NK  Natural Killer cell
NSG  NOD/Scid/Il2rg-/- 
PAGE  PolyAcrylamide Gel Electrophoresis
PBMC  Peripheral Blood Mononuclear Cells
PCA  Protein fragment Complementation Assay
PCR  Polymerase Chain Reaction
PD1  Programmed Death 1
PD-L1  Programmed Death Ligand 1
PLA  Proximity Ligation Assay 
PPI   Protein-Protein Interaction
qPCR  quantitative PCR
Rag  Recombination activating gene
RGD  Arginine-Glycine-Aspartic acid
RNA  Ribonucleic Acid
RRS  Ras Recruitment System
R-SMAD Receptor-associated SMAD
RT-PCR  Reverse Transcriptase Polymerase Chain Reaction
SCINEX-P Screening for Interactions between Extracellular Proteins
siRNA  small interfering Ribonucleic Acid
Smurf  Smad ubiquitination regulatory factor
snRNA  small nuclear Ribonucleic Acid 
SRS  SOS Recruitment System 
STAT  Signal Transducer and Activator of Transcription
TAP  Tandem Affinity Purification
TCR  T Cell Receptor
TEV  Tobacco Etch Virus
TF  Transcription Factor
TGF-β  Transforming Growth Factor beta
TGFβR  Transforming Growth Factor beta Receptor
Th  T helper lymphocyte
TRAMP  Transgenic Adenocarcinoma of Mouse Prostate
Treg  regulatory T lymphocyte
TSP-1  Thrombospondin 1
tTreg  thymic Treg
UAS  Upstream Activating Sequence
UPR  Unfolded Protein Response 
UPRE  Unfolded Protein Response Element
WB  Western Blot
WT  Wild-Type
 
xGVHD  xenogeneic Graft Versus Host Disease 
Y2H  Yeast two-Hybrid
YFP  Yellow Fluorescent Protein
14
Summary
Regulatory T lymphocytes (Tregs) are a subset of CD4+ T cells endowed with immunosuppressive 
activity. They inhibit immune responses through various mechanisms, which include the production 
of the immunosuppressive cytokine Transforming Growth Factor beta 1 (TGF-β1).  
Many cell types produce TGF-β1 in a latent form, in which the mature TGF-β1 cytokine is non-
covalently associated to the Latency Associated Peptide (LAP). In this latent conformation, mature 
TGF-β1 is prevented from binding to its receptor by LAP.  To become active, mature TGF-β1 must 
be released from LAP, a process referred to as TGF-β1 activation.  
Human Tregs, but not other types of T cells, produce active TGF-β1 upon TCR stimulation. The 
molecular mechanisms leading to TGF-β1 activation by Tregs are not yet fully elucidated.  TCR-
stimulated Tregs present latent TGF-β1 on their surface through binding to a transmembrane protein 
called GARP.  Antibodies against GARP block active TGF-β1 production by Tregs, demonstrating 
that GARP is required for TGF-β1 activation by  these cells.  However, forced expression of GARP 
in non-regulatory  T cells is not sufficient to induce active TGF-β1 production. We thus 
hypothesised that additional proteins, present in Tregs but  not in other types of T cells, associate 
with GARP/latent TGF-β1 complex and contribute to TGF-β1 activation. The aim of our project 
was to identify such protein(s). 
To achieve our objective, we used two different approaches.  In the first, we used GARP as bait to 
screen a Treg cDNA library by yeast two-hybrid. This lead to the identification of LAPTM4B 
(Lysosomal-Associated Protein Transmembrane 4B), a multipass transmembrane protein encoded 
by a gene expressed at higher levels in Tregs than in other T cells. We show that LAPTM4B 
decreases cleavage of pro-TGF-β1, secretion of soluble latent TGF-β1 and surface presentation of 
GARP/TGF-β1 complexes by  Tregs, but does not contribute to TGF-β1 activation. We thus 
concluded that LAPTM4B is a negative regulator of TGF-β1 production by human Tregs. In a 
second approach, we identified proteins that co-immunoprecipitate with GARP in human Tregs by 
Mass Spectrometry. This allowed for the identification of 7 candidates that display  higher 
expression in Tregs compared to other T cells. To date, we excluded 4 of these candidates from 
further analysis, because they did not induce TGF-β1 activation in 293T cells expressing GARP and 
TGF-β1. The remaining 3 candidates have not been tested in this assay yet and may  represent Treg 
proteins that cooperate with GARP to activate TGF-β1.
Altogether, we have identified LAPTM4B, a Treg protein which may play  a role in regulating 
immune responses by  decreasing TGF-β1 production by, and thus function of human Tregs.  We 
have also identified 3 additional putative GARP-binding proteins which could also regulate Treg 
function.  Further analyses are ongoing to determine what role, if any, these proteins play in the 
control of active TGF-β1 production by human Tregs.
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Introduction
1. Regulatory T lymphocytes and cancer
1.1. Cancer immunotherapy
The development of immunotherapies against cancer emerged from the discovery of T lymphocytes 
directed against tumours in cancer patients. Despite the development of spontaneous T cell 
responses against  their tumours, melanoma patients fail to reject their cancers.  Immunotherapies 
aiming at  increasing the frequency and/or the effector functions of tumour-specific T lymphocytes 
could overcome this inefficient anti-tumour response and lead to tumour rejection. They  are 
particularly attractive since they  are expected to yield less side effects than conventional anti-cancer 
treatments (Boon et al. 2006, Coulie et al. 2014).  For this reason a huge effort has been made over 
the last decades to develop immunotherapeutic strategies against cancers.  
The first gene encoding a human tumour-specific antigen was identified in 1991 by the group of T. 
Boon and called MAGEA1 (van der Bruggen et al. 1991).  This gene was found to be expressed by 
tumours but not by other healthy tissues, and was therefore an ideal target for immunotherapeutic 
strategies based on the use of vaccines.  Since this discovery, various other genes encoding tumour 
specific antigens were identified. These findings paved the way to the development of therapeutic 
vaccines using antigens to boost anti-tumour immunity.   Various vaccination modalities were tested 
in patients, including injections of peptides, recombinant proteins or viruses, and dendritic cells 
pulsed with peptides (Boon et al. 2006, Coulie et al. 2014).   Unfortunately, clinical responses to the 
vaccines were lower than expected, and occurred in only 5 to 10% of cancer patients.
Besides vaccination approaches, other immunotherapeutic strategies to boost pre-existing T cell 
function were recently elaborated.  These therapies, used alone or in combination with vaccinations, 
consist in injecting antibodies blocking T-cell receptors whose involvement with their cognate 
ligand induces inhibitory signals in T cells. They were termed immune checkpoints therapies.  Anti-
CTLA4 (Cytotoxic T lymphocyte Antigen 4) antibodies were the first «checkpoint» inhibitor tested 
in clinical trials for treatment of metastatic melanoma (Hodi et al. 2010).  Given the improvement 
of overall survival of melanoma patients who received anti-CTLA4 treatment, this treatment 
received Food and Drug Administration (FDA) approval for advanced melanoma treatment (Pardoll 
2012, Page et al. 2014). The benefits of this therapy was considerable and lead to the development 
of a second generation of checkpoint inhibitors, namely anti-Programmed Death 1 (PD1) and anti-
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Programmed cell Death Ligand 1 (PD-L1) antibodies.  These antibodies have recently  shown 
clinical activity and safety in phase I trials (Brahmer et al. 2012, Topalian et al. 2012).  
Notwithstanding successes of anti-CTLA4, anti-PD1 or anti-PD-L1 therapies in some patients, 
many do not respond to these immunostimulatory therapies, and this appears to result from the 
immunosuppressive environment that  prevails inside tumours.  Numerous mechanisms to inhibit 
anti-tumour immunity are elaborated by cancer cells. Cancer cells themselves produce soluble 
immunosuppressive molecules like Transforming Growth Factor beta 1 (TGF-β1), IL-10, galectins 
and Indoleamine 2,3-Dioxygenase (IDO) (Chen et al. 1994, Gorelik and Flavell 2001, Uyttenhove 
et al. 2003, Demotte et al. 2008, Coulie et al. 2014). In addition, non-cancerous cells displaying 
immunosuppressive functions are also recruited within the tumour (Nishikawa and Sakaguchi 
2014). These include regulatory  T lymphocytes, or Tregs. It  is thought that  blocking 
immunosuppression in the tumor environment could improve the efficiency of cancer vaccines or 
immunostimulatory antibodies.
1.2. Regulatory T cells 
The existence of a T cell population displaying suppressive activity was initially proposed by 
Nishizuka and Sakakura in 1969 (Nishizuka and Sakakura 1969). These cells were named 
«Suppressor T cells», but were renamed «Regulatory  T lymphocytes» or Tregs by  Sakaguchi in 
1995 (Sakaguchi et al. 1995).  Tregs participate to the maintenance of tolerance to self.  Tolerance 
of T cells against self-antigens is ensured at two levels. Negative selection of developing self-
reactive T cells in the thymus is often referred to as a «central» mechanism of tolerance, whereas 
«peripheral» mechanisms also exist to control self-reactive T cells that escape negative selection 
and reach peripheral organs. Tregs play  an indispensable role in the maintenance of peripheral 
tolerance, by keeping in check autoreactive T cells (Josefowicz et al. 2012).  Tregs appear also to 
restrain immune responses against pathogens to avoid excessive immune reactions and damage to 
host tissues (Belkaid and Tarbell 2009).  
Tregs represent a small fraction of the circulating CD4+ T cell population.  Several protein markers 
have been proposed to distinguish them from conventional, non-regulatory CD4+ T cells.  In order 
to study  their function, researchers in the field put a lot of effort into the discrimination of Tregs 
from other conventional T cells (Figure 1).  In 1995, Sakaguchi and co-workers showed that  CD4+ 
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T cell constitutively expressing high levels of CD25, the α chain of the IL-2 receptor, displayed 
suppressive activity (Sakaguchi et al. 1995).  Unfortunately, CD25 is not  strictly specific of Tregs 
since all T cells acquire surface CD25 upon TCR stimulation.  Other surface markers like CD127 
and CTLA4 were also proposed to discriminate the Tregs from other T cells but, as for CD25, their 
expression is modulated upon TCR stimulation, precluding their use as strictly  specific Treg 
markers.  In the early 2000s, mutations in a gene called Foxp3, located on the X-chromosome, were 
identified as responsible for the development of a severe lymphoproliferative autoimmune disease 
in both mice and humans (Chatila et al. 2000, Bennett et al. 2001, Brunkow et al. 2001, Wildin et 
al. 2001).  In humans, this disease is known as IPEX (Immune dysregulation, Polyendocrinopathy, 
Enteropathy, X-linked syndrome).  Shortly after this finding, three groups showed that gene foxp3 
codes a transcription factor that is indispensable for Treg development and function and that the 
phenotype of mice with spontaneous or targeted Foxp3 mutations is due to a Treg deficiency 
(Fontenot et al. 2003, Hori et al. 2003, Khattri et al. 2003).  Expression of Foxp3 is specific of the 
Treg lineage in mice.  In humans however, FOXP3 expression is not  strictly  limited to Tregs as 
TCR stimulation induces transient FOXP3 expression in non-regulatory T cells.  Therefore, FOXP3, 
although essential for Treg differentiation, maintenance and function, cannot serve as a reliable Treg 
marker in humans (Morgan et al. 2005, Roncador et al. 2005).  
To date, the only molecular marker that unambiguously distinguishes human Tregs from other T 
cells is the demethylation of a regulatory region in intron 1 of the FOXP3 gene.  This region, 
termed FOXP3i1, CNS2 or TSDR, contains CpGs that are demethylated in human and murine Tregs 
while they are methylated in non-regulatory T cells.  Demethylation of FOXP3i1 ensures stable 
FOXP3 expression.  The methylation status of this region can be assessed by sequencing or by 
methylation-specific quantitative PCR (MS-qPCR) on sodium bisulfite-treated genomic DNA 
(Baron et al. 2007, Floess et al. 2007, Wieczorek et al. 2009, Stockis et al. 2009a). This molecular 
marker, although highly reliable to discriminate Tregs in humans, cannot be used to sort cells from 
tissue or blood samples, but can serve to measure the proportion of Tregs in a given sample.  It can 
also serve to characterise clones of human CD4+ T cells, to distinguish Treg from non-regulatory T 
helper (Th) clones (Stockis et al. 2009a).  
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Figure 1. Schematic representation of regulatory and non-regulatory markers.
Regulatory T cells (Tregs) are characterised by their suppressive function and their anergy in the absence of 
exogenously added cytokine. Molecules such as CD25, CTLA-4 and CD127 are differentially expressed on Tregs by 
comparison to other CD4+ T cells.  However,  their expression is also modified during non-regulatory T cell activation, 
rendering them inadequate to unambiguously discriminate Tregs from recently activated T cells.  The most specific 
molecular marker of human Tregs is the stable demethylation of a region of the intron 1 of gene FOXP3.
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1.3. Tregs in cancer
Because Tregs are a T cell subset specialised in the inhibition of immune responses, they are 
thought to play a deleterious role in cancer.  Evidence for this was provided in multiple murine 
models. In 1999, Onizuka and co-workers demonstrated that, reduction of Treg numbers by 
administration of a depleting anti-CD25 antibody reduced the growth of transplanted tumors in six 
out of eight models tested (Onizuka et al. 1999).  The same year, the group  of Sakaguchi used a 
model in which nude mice (athymic mice) were co-transplanted with syngeneic leukemia and 
splenic cells (Shimizu et al. 1999).  They observed that when splenocytes were depleted from 
CD25+ T cells prior to transfer, mice succeeded in eradicating the transplanted leukemia.  From 
these initial studies and all the evidence accumulated over the last 15 years, it is now clear that 
Tregs favours cancer development (Nishikawa and Sakaguchi 2014). Interestingly, recent studies in 
mouse melanoma models revealed that  anti-CTLA4 antibody treatment thought so far to block 
inhibitory effect of CTLA4 on T cells, appears to act also partially by depleting tumor-infiltrating 
Tregs (Simpson et al. 2013).
In humans, the lack of a reliable protein marker of Tregs constitutes a major obstacle to the analysis 
of their role in cancer.  Many studies report increased frequencies of FOXP3+ cells in the blood of 
cancer patients by comparison to healthy  controls, and some show correlations between high 
FOXP3+ T cells/Th or FOXP3+ T cells/CTL ratios and poor prognosis (Colombo and Piconese 
2007).  However, as stated above, FOXP3 is also expressed in activated T cells, rendering the 
interpretation of these observations difficult. Our group used methylation-specific PCR for 
FOXP3i1 to evaluate frequencies of Tregs with a demethylated FOXP3i1 in the blood of cancer 
patients having received immunomodulatory  drugs (de Vries et al. 2011). These drugs were 
expected to induce reductions in Treg numbers hoping to favour tumour rejection.  They included 
anti-CD25 monoclonal antibodies, low dose cyclophosphamide and IL-2/diphteria toxin fusion 
protein .  Our results indicated that none of the Treg-depleting therapies led to a significant decrease 
in Treg frequencies in the blood of treated patients.  Thus, it remains still difficult to evaluate the 
role of Tregs in human cancer patients.
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1.4. Mechanisms of immunosuppression by murine and human Tregs
Many different suppression mechanisms have been described for mouse Tregs. They include 
expression of inhibitory surface receptors and secretion of inhibitory  soluble molecules. Treg 
suppression can be due to a direct effect on effector T cells, or to indirect  effects on antigen 
presenting cells, leading to decreased effector T cell activation (Vignali et al. 2008).  Which 
mechanism is used by human Tregs in various physiological or pathological contexts is not known. 
We will summarise below the major suppressive mechanisms described for mouse Tregs.
  
A first mechanism that appears to play an important role in murine Treg suppression is mediated by 
surface CTLA4. CTLA4 is a receptor expressed at the surface of activated T cells which binds B7.1 
(CD80) and B7.2 (CD86) molecules on the surface of antigen presenting cells.  Engagement of 
CTLA4 induce inhibitory signals in T cells.  The role of CTLA4 in Treg function was underlined by 
the Foxp3-Cre x Ctla4fl/fl mouse model.  These mice lack CTLA4 expression on Tregs.  They 
display  signs of autoimmunity, suggesting a role for CTLA4 in Treg function.  However their 
phenotype is milder than that of Foxp3 knock-out mice: Foxp3-Cre x Ctla4fl/fl die within seven 
weeks of age, whereas Foxp3-/- die within 3 weeks (Wing et al. 2008).  This indicates that CTLA4 
is probably  not the only  molecule important for proper Treg function. In addition, how CTLA4 
expression on Tregs could mediate Treg function was not clear.  A molecular explanation was 
proposed by Qureshi and co-workers, who showed that B7 expression on dendritic cells (DCs) is 
reduced upon engagement of CTLA4 expressed on Tregs (Qureshi et al. 2011).  A second 
explanation is that interaction between CTLA4 on Tregs and B7 on DCs induces a production of 
IDO by the latter providing an immunosuppressive environment (Fallarino et al. 2003, Shevach 
2009).  
A second proposed mechanism is the «IL-2 sink».  Because Tregs constitutively  express high levels 
of CD25 (the high affinity  subunit of the IL-2 receptor), they may locally  deprive effector T cells of 
IL-2.  In this manner, IL-2 is prevented to stimulate proliferation of effector T cells (de la Rosa et 
al. 2004).  However, this mechanism remains controversial and difficult to prove in vivo.  
Third, Tregs were shown to mediate cytolysis of target cells through secretion of Granzyme A, 
Granzyme B and perforin (Grossman et al. 2004, Cao et al. 2007, Zhao et al. 2007, Boissonnas et 
al. 2010).
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A fourth suppression mechanism described is the production of cAMP and adenosine.  Both 
molecules have anti-proliferative effects on T cells but can also negatively  regulate DCs 
(Josefowicz et al. 2012).  Bopp et al. observed that Tregs express high levels of intracellular cAMP 
which can be transferred to target effector T cells by gap junctions (Bopp  et al. 2007, Huang et al. 
2009).  cAMP then inhibits T cell proliferation by decreasing IL-2 production (Bodor et al. 2001). 
Adenosine is also produced abundantly  by  Tregs. It binds to adenosine A2AR receptors on 
neighbouring T cells and induces T cell growth inhibition in vitro. This mechanism was 
demonstrated to play  a role in two reports.  A defect in Treg suppressive function in vivo was 
observed when Tregs are unable to produce adenosine in a skin allograft rejection model (Deaglio et 
al. 2007), and T cells from A2AR-/- mice failed to be suppressed by  Tregs in a colitis model 
(Naganuma et al. 2006).
Finally, Tregs produce well-known immunosuppressive molecules that may also inhibit immune 
cell function. Mainly, IL-10 and TGF-β1 were shown to play crucial roles in Treg-mediated 
suppression (Rubtsov et al. 2008).  A detailed chapter on TGF-β will follow.
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Mechanisms of suppression by human Tregs are more difficult to study, notably because of the lack 
of an appropriate protein marker to identify these cells.  Our group is trying to study human Treg 
suppression, and has chosen to use clones of human Tregs characterised by demethylated FOXP3i1 
as a source of stable, and molecularly defined Treg cells.  By comparing transcriptional profiles of 
human Treg clones to those of clones of non-regulatory T cells (Th and CTL clone, characterised by 
a methylated FOXP3i1), we found that Tregs produce the active form of the immunosuppressive 
cytokine TGF-β.  Active TGF-β produced by  Tregs acts in autocrine fashion in Tregs themselves, 
but also in paracrine fashion on Th cells co-cultured with Tregs.  The immunosuppression exerted 
by human Treg clones in vitro can be prevented at least in part with neutralising anti-TGF-β 
antibodies (Stockis et al. 2009a).  We thus decided to focus our analyses of human Treg suppression 
by studying the mechanism by which Tregs produce the active form of TGF-β.
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2. TGF-β1, an immunosuppressive cytokine
2.1. TGF-β1 synthesis, processing and activation
Transforming Growth Factor-β1 (TGF-β1) belongs to the TGF-β superfamily  that  comprises in total 
33 ligands encoded by the human genome. It includes TGF-βs, the Bone Morphogenetic Proteins 
(BMPs), activins, Growth and Differentiation Factors (GDFs) and Nodal (Chang et al. 2002). 
Mammals express three isoforms of TGF-β (TGF-β1, 2 and 3) encoded by three different genes. 
TGF-β ligands as well as their receptors are expressed by almost every cell in the organism. They 
have pleiotropic effects on cell proliferation, differentiation, migration and survival and affect many 
biological processes. TGF-β1 is the predominant isoform expressed in the immune system.  T cells, 
B cells, NK cells, DCs and platelets produce this cytokine (Assoian et al. 1983, Li et al. 2006). 
TGF-β production is a tightly regulated process.  Although little is known about the regulation of 
the transcription of the TGFB1 gene, the steps leading to the production of bioactive TGF-β 
molecule have been extensively studied.  
TGF-β is produced as an inactive precursor, the pre-pro-TGF-β (Figure 2).  Pre-pro-TGF-β include, 
a signal peptide allowing targeting to the endoplasmic reticulum (ER).  After cleavage of the signal 
peptide, the resulting pro-TGF-β dimerise and undergoes a second proteolytic cleavage by Furin 
(Dubois et al. 1995, Dubois et al. 2001). This leads to a large N-terminal fragment called the 
latency-associated peptide (LAP), and a short C-terminal fragment corresponding to the mature 
TGF-β cytokine (Gentry et al. 1988, Miyazono et al. 1988, Travis and Sheppard 2014).  Mature 
TGF-β remains non covalently bound to the LAP and in this conformation, called «latent TGF-β», 
the mature TGF-β is prevented from binding to its receptor and exerting an activity  (Travis and 
Sheppard 2014).  
In some cell types, latent TGF-β is covalently bound to Latent TGF-β Binding Protein (LTBP).  One 
LTBP molecule associates to a latent TGF-β dimer by  forming disulphide bonds with Cysteines 33 
(Cys33) of each LAP monomer.  Not all cell types produce latent TGF-β in complexes with LTBP. 
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Figure 2. Schematic representation of TGF-β1 processing.
TGFB1 gene is transcribed and translated as a pre-pro-protein. Once it has reached the ER, the signal peptide is cleaved 
and two TGF-β1 molecules dimerise forming the pro-TGF-β1 homodimer. Pro-TGF-β1 is further cleaved by Furin into 
2 parts: the N-terminal fragment or the Latency-Associated Peptide (LAP), and the C-terminal fragment or mature TGF-
β1. After cleavage, LAP and mature TGF-β1 remain non-covalently associated to each other forming the latent TGF-β1. 
This complex is inactive and can either be secreted as such or as part of a larger complex in which latent-TGF-β1 is 
covalently bound to Latent TGF-β Binding Protein (LTBP). Latent TGF-β1 secreted alone or associated with LTBP is 
inactive and require an additional step of activation that releases the active TGF-β1 from the LAP.
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The tridimensional structure of latent TGF-β1 was recently revealed by X-ray  crystallography (Shi 
et al. 2011 and Figure 3). The latent TGF-β1 has a ring-like shape in which two «arms», 
corresponding to the two LAP monomers encircle the mature TGF-β1 dimer. The two LAP 
monomers overlap with one another at their extremities. On their C-terminus, they  are linked to 
each other by two interchain disulphide bounds, forming a so-called «neck» in the structure. On 
their N-terminus, they overlap to form a «straitjacket-like» structure surrounding the mature TGF-β 
dimer.  An RGD motif (arginine-glycine-aspartic acid) is present at the «shoulders» of the structure 
(close to the C-terminus) and the Cys33 residues, which can bind LTBP, are at the opposite side in 
the straitjacket, close to the N-terminus.  In this rigid structure, all the contact sites of mature TGF-β 
with its receptor are rendered inaccessible by LAP (Shi et al. 2011, Travis and Sheppard 2014).
All cells secrete TGF-β in its latent inactive form. To exert  its function through binding to its 
receptor, mature TGF-β must be released from the LAP, a process referred to as TGF-β activation. 
Several mechanisms of TGF-β activation, which appear to vary  from one cell type to another, were 
described in in vitro and in vivo models (Travis and Sheppard 2014).
Activation of TGF-β in vitro is easily  achieved by  inducing protein denaturation. For example, heat, 
extremes of pH, ionizing radiation and chaotropic agents can all activate TGF-β (Travis and 
Sheppard 2014).  In the blood flow, latent TGF-β bound to LTBP is produced mainly by platelets, 
and undergoes activation due to action of shear forces (Ahamed et al. 2008).  Reactive oxygen 
species were also shown to activate TGF-β in vitro (Barcellos-Hoff and Dix 1996).  
The mechanisms involved in TGF-β activation in vivo are of course more difficult to study.  Several 
mechanism were proposed. One appears to involve Thrombospondin-1 (TSP-1), a large 
homotrimeric protein produced by many cell types and secreted in the extracellular matrix.  A short 
peptide in TSP-1 (KRFK) was shown to bind to a specific sequence of LAP (LSKL), and interfere 
with LAP binding to mature TGF-β, hence activating the cytokine through release of mature TGF-β 
(Schultz-Cherry et al. 1995, Ribeiro et al. 1999).  This activation mechanism was first identified in 
vitro but was later confirmed to be relevant in vivo by the group of N. Bouck (Crawford et al. 
1998).  Tsp1-/- mice manifest inflammation in several organs that is similar to that observed in 
Tgfb1-/- mice.  Interestingly, treating Tsp1-/- mice with a KRFK peptide suppressed inflammation in 
lung and  pancreas (Crawford et al. 1998).  In the same line, wild-type mice treated with a LSKL 
peptide inhibiting Tsp-1 mediated activation induced inflammation in lung and pancreas.  Those 
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data strongly suggests an involvement of Tsp-1 in TGF-β1 activation in vivo.  However, the 
phenotype of the Tsp1-/- mice is not as severe as that of Tgfb1-/- mice, suggesting that other 
mechanisms play important roles in TGF-β1 activation in vivo.  
Figure 3. Schematic representation of the latent TGF-β1 complex.
Latent-TGF-β1 complex is composed of a dimer of LAP and a dimer of mature TGF-β1. As revealed in its crystal 
structure (Shi et al. 2011), latent TGF-β1 forms a ring-shaped complex, where the LAP dimer encircles the mature 
TGF-β1 dimer.  LAP monomers bind to each other through disulfide bonds at their C-termini (C-C bonds are 
represented by orange lines), forming the «neck» of the complex. RGD sequences can be found at the «shoulders», 
while the N-terminal parts form the «arms», bearing cysteine residues (Cys33) at their «wrists». LTBP can form 
disulfide bounds with these two Cys33 in LAP.  Release from the LAP of mature TGF-β1 can occur when tensile forces 
are powered on the LAP by integrins through binding to the RGD motifs on one side and by binding to LTPB proteins 
on the other side.
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Integrins are a family  of heterodimeric transmembrane receptors comprising an α and a β chain that 
are involved in various cellular processes including cell adhesion, proliferation and migration.  A 
subset of integrins bind to proteins containing an RGD motif.  At least eight integrins (αvβ1, αvβ3, 
αvβ5, αvβ6, αvβ8, αIIbβ3, α5β1, α8β1) of the 24 mammalian integrins bind to RGD-containing 
proteins.  The presence of an RGD motif in the LAP suggests a potential interaction between latent 
TGF-β and integrins.  The role of integrins in TGF-β1 activation in vivo was studied in several 
mouse models.  In 2007, the group  of J. Munger created a mouse with a knock-in mutation in the 
Tgfb1 gene changing the TGF-β1 RGD motif into an RGE non-functional motif.  So-called 
Tgfb1RGE/RGE mutant  mice display the lethal multi-organ inflammation and autoimmunity phenotype 
of the Tgfb1-/- mice, despite production of normal levels of latent TGF-β1 (Yang et al. 2007). 
Authors concluded that RGD-binding integrins are requisite latent  TGF-β1 activators in the immune 
system.  However which integrins are implicated is not completely understood yet.  Two integrins, 
avβ6 and avβ8, were clearly shown to activate TGF-β in some cell types (Munger et al. 1999, Mu et 
al. 2002).  
Expression of αvβ6 was reported to be restricted to epithelial cells.  In vitro, cells expressing αvβ6 
were shown to activate TGF-β in co-cultures with a reporter cell line expressing the luciferase gene 
under the control of a TGF-β responsive promoter.  TGF-β signalling in this system was abolished 
with anti-αvβ6 antibodies. Separating reporter cells from αvβ6 expressing cells with a semi-
permeable membrane also prevented TGF-β signalling in the reporter cells, suggesting a 
requirement for cell-cell contact to achieve paracrine action of TGF-β  (Huang et al. 1996, Munger 
et al. 1999).  In vivo, involvement of the β6 integrin subunit in TGF-β activation was demonstrated 
in Itgb6-/- mice, which display exaggerated inflammatory  responses and are protected from tissue 
fibrosis at multiple sites, a process known to rely on TGF-β production (Munger et al. 1999).  These 
phenotypes revealed an important role of the β6 subunit in TGF-β activation in vivo.  However, the 
pathology developed in Itgb6-/- mice is again less severe than that of Tgfb1-/- mice, meaning that 
other integrins are involved in TGF-β activation in vivo.
Itgb8-/- mice show abnormal vascular development and die during embryonic development or 
shortly after birth, precluding analyses of the role of β8 integrins in TGF-β activation after birth. 
Tissue specific deletions of Itgb8 were therefore developed (Travis et al. 2007). Mice lacking 
integrin β8 in leukocytes (Vav1-Cre x Itgb8fl/fl) develop severe autoimmunity over time. To 
discriminate which immune cells were responsible for this phenotype, the authors generated 
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CD11c-Cre x Itgb8fl/fl  to create a DC specific deletion of Itgb8.  They also generated CD4-Cre x 
Itgb8fl/fl mice to create a T cell-specific deletion of integrin β8 (Travis et al. 2007).  Whereas mice 
lacking Itgb8 in DCs suffered from severe autoimmunity, identical to that of mice with an Itgb8 
deficiency in all leukocytes, mice lacking Itgb8 on T cells were undistinguishable from WT mice 
for over 14 months of age.  Those results strongly  suggest that  the autoimmune phenotype of mice 
lacking integrin β8 is largely due to a lack of Itgb8 in DCs.  Integrin β8-deficient DCs were also 
shown to fail to induce Treg and Th17 differentiation in vivo, two differentiation processes known 
to depend on TGF-β signalling (Travis et al. 2007, Acharya et al. 2010, Worthington et al. 2011, 
Kudo et al. 2012).
The crystal structure of latent TGF-β provided a model for a mechanical description of integrin-
mediated TGF-β activation (Shi et al. 2011).  A traction on the LAP could be exerted by integrins 
through their binding to the RGD motifs at the C-terminus of the LAP.   Disulphide links between 
Cys33 at the opposite N-terminus and LTBP proteins tether LAP to the extracellular matrix, 
allowing the tensile force exerted by integrins to release the mature TGF-β from the LAP 
straitjacket (Figure 3).  
Altogether, these models point to a role for Tsp-1, αvβ6 and αvβ8 integrins in latent TGF-β 
activation in vivo.  But none indicate which molecule is implicated in active TGF-β production by 
Tregs.
2.3. TGF-β signal transduction
Upon release from the LAP, mature TGF-β binds to its receptors expressed in virtually all cell 
types. All three isoforms of TGF-β bind to a common receptor complex, a hetero-tetrameric 
structure composed of two «type I» and two «type II» TGF-β receptor chains (TGFβRI and 
TGFβRII, Figure 4). TGF-β first  binds to a TGFβRII homodimer, which then recruits a TGFβRI 
homodimer. Both TGFβRI and TGFβRII are serine/threonine kinases. The TGFβRII chains are 
constitutively active. Upon TGF-β engagement, TGFβRI is recruited, phosphorylated and activated 
by TGFβRII.  
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Figure 4. Schematic representation of the canonical TGF-β signalling pathway.
Active TGF-β signals through a tetrameric receptor complex composed of two TGFβRII and TGFβRI. TGF-β binds first 
to the TGFβRII dimer, which recruits and phosphorylates TGFβRI. Once phosphorylated TGFβRI is active and 
phosphorylates the R-Smads (Smad2/3) transcription factors. Phosphorylated Smad2/3 bind Smad4,  allowing nuclear 
translocation of the heteromeric complex. In the nucleus, Smad complexes act in association with diverse cofactors to 
induce or repress the transcription of numerous genes.
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The activated receptor complex than activate transcription factors of the Smad family.  In mammals, 
there are five receptor-associated Smads or R-Smads (Smad1, 2, 3, 5 and 8), one common Smad or 
co-Smad (Smad4) and two inhibitory Smads or I-Smads (Smads 6 and 7). Activated TGFβRI 
recruits and phosphorylates R-Smads on C-terminal serines (Massague et al. 2005, Itoh and ten 
Dijke 2007). Once phosphorylated, Smads form a trimeric structure with the co-Smad, Smad4. 
Trimeric complexes comprising Smad 2, 3 and 4 recognise a consensus DNA sequence (5’-
AGAC-3’), albeit with low affinity (Zawel et al. 1998).  Smad transcription factors thus require 
association with other factors to increase their DNA binding and ensure full transcriptional activity. 
Depending on the physiological context, the Smad trimeric complexes will associate with different 
co-activators or co-repressors and thus up  or downregulate expression of hundreds of genes that 
depend on nature of the associated co-factors (Xu et al. 2012).  
In addition to the canonical TGF-β pathway, TGF-β also triggers Smad-independent signalling 
pathways, including MAP kinases, PI3 kinase and Rho GTPases (Travis and Sheppard 2014). 
Several mechanisms modulate the intensity and the duration of TGF-β signals.  One important 
negative feedback relies on induction of I-Smads, which are recruited to TGFβRI and prevent 
Smad2/3 binding and activation.  I-Smads also promote TGFβRI inactivation and degradation 
through recruitment of phosphatases and E3-Ubiquitin ligases known as Smurfs (Smad 
Ubiquitination Regulatory Factors). Other inhibitory pathways inactivated R-Smads by 
dephosphorylation or by ubiquitination-induced degradation (Itoh and ten Dijke 2007, Xu et al. 
2012, Travis and Sheppard 2014).  
2.4. TGF-β functions in the immune system
TGF-β exerts plethora of effects on different cell types, both in physiological contexts and in 
diseases.  We will here focus only on the role of TGF-β in the immune system.  TGF-β can inhibit 
the proliferation, induce the apoptosis and modulate the cell differentiation of immune cells (Travis 
and Sheppard 2014).  
TGF-β plays a crucial role in the maintenance of peripheral tolerance, as best illustrated by the 
severe autoimmune phenotype of Tgfb1-/- mice (Shull et al. 1992, Kulkarni et al. 1993).  These mice 
die less than three weeks after birth of a wasting syndrome accompanied by a multifocal 
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inflammatory cell infiltration of tissues, leading to organ failure. TGF-β1 is thus a potent 
immunosuppressive molecule.  However, TGF-β can be made by and act  upon many immune cell 
types meaning that the severe phenotype observed in those mice can involve many different players. 
Therefore, several mouse models were developed to identify the main TGF-β producers and targets.
2.4.1. TGF-β production by T cells 
Several mouse models in which the Tgfb1 gene is deleted in T cells revealed that T cells are 
important but not exclusive TGF-β1 producers in vivo.  In 2007, Li and co-workers observed that 
CD4-Cre x Tgfb1fl/n mice develop early lethal immune pathology in multiple organs associated with 
enhanced T cell proliferation and activation (Li et al. 2007).  In 2011, the same group reported the 
phenotype of OX40-Cre x Tgfb1fl/n mice.  In these mice, Tgfb1 production is abrogated in a subset 
of T cells only, namely in Tregs and activated T cells rather than in all naïve T cells like in the CD4-
Cre model.  This time, they observed milder signs of autoimmunity, with a less severe wasting 
disease and colitis beginning only at around 5 months of age.  The authors concluded that TGF-β1 
produced by Tregs and/or activated CD4+ T cells is required to protect  mice from the development 
of an inflammatory disorder in aging mice (Gutcher et al. 2011).  This suggests that in this latter 
model other sources of TGF-β1 such as CD8+ T cells or naïve CD4+ T cells contribute to the 
maintenance of tolerance. 
Finally, Foxp3-Cre x Tgfb1fl/n mice which carry a Tgfb1 deletion in Tregs only, are healthy mice and 
show no sign of autoimmunity.  They do show increased frequencies of Foxp3+ Tregs in the 
periphery, indicating that Treg-derived TGF-β1 is required for the inhibition of Treg proliferation, 
but not for the maintenance of peripheral tolerance (Gutcher et al. 2011).  In the same line, Tgfb1-/- 
Tregs  were shown to be as protective as WT CD4+CD25+ Tregs against colitis in a T cell tranfer 
model (Fahlen et al. 2005).  Since the suppressive activity of Tregs in this model was still inhibited 
by an anti-TGF-β1 antibody, it was suggested that Treg function relied on TGF-β activation even 
though the source of latent TGF-β was probably not the Tregs themselves (Fahlen et al. 2005). 
These results seem to indicate that TGF-β1 produced by  Tregs themselves is not required for Treg 
suppressive function and immune homeostasis in vivo. Contradictory results in adoptive transfer 
model suggest in contrast that  Treg suppression is dependent on TGF-β1 production.  Mamura et al. 
transferred Tgfb1-/- splenocytes depleted of Tregs into Rag2-/- recipients. This induced autoimmune 
inflammatory disease in the recipient mice, which could be suppressed by co-transfer of Tgfb1+/+ 
Tregs, but not or only partially by Tgfb-/- Tregs (Mamura et al. 2004).  Similarly, Li et al. showed 
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that lymphopenic hosts are protected from the development of colitis induced by the transfer of 
naïve CD4+ T cells if WT Tregs, but not Tgfb1-/- Tregs, are co-transferred (Li et al. 2007).  Theses 
results demonstrated an essential role for Treg-cell-produced TGF-β1 in inhibiting colitis in 
adoptive transfer models, and led to the conclusion that  TGF-β1 production by Tregs themselves is 
important for their suppressive activity. Further work will thus be needed to clarify those 
contradictory results.
2.4.2. T cells as targets of TGF-β in the immune system
To determine which cells are targeted by TGF-β1 in vivo, Tgfb1-/- mice were crossed with mice 
lacking MHC class II molecules and thus CD4+ T cells (Letterio et al. 1996).  These mice were 
substantially  protected from inflammation, indicating that  CD4+ T cells are important  mediators of 
the phenotype of Tgfb1-/- mice, and are probable important targets of TGF-β1 in vivo.  To address 
the importance of T cells as major direct  targets for TGF-β in vivo, Gorelik and Flavell generated 
mice expressing a dominant-negative (dn) TGFβRII specifically in T cells.  These mice developed 
excessive T cell activation and age-related wasting disorder associated with multiorgan 
inflammation and development of autoantibodies (Gorelik and Flavell 2000).  The disease was 
similar but not as severe as the one observed in Tgfb1-/- animals.  This could be explained by 
incomplete inhibition of TGF-β signalling in cells expressing the dnTGFβRII.  Subsequently 
therefore, three studies examined the effect of a conditional deletion of Tgfbr2 or Tgfbr1 genes in T 
cells using CD4-Cre mice.  Complete abolition of TGF-β signalling in T cells results in a phenotype 
akin to the Tgfb1-/- mice (Li et al. 2006, Marie et al. 2006, Liu et al. 2008).  These models definitely 
demonstrate a central role for TGF-β signalling in T cells for the maintenance of tolerance.  More 
recently  however, Zhang and Bevan questioned this interpretation based on their results obtained 
with dLck-Cre x Tgfbr2fl/fl mice.  In this model, TGF-β signalling is abolished much later in 
developing T cells than in CD4-Cre mice.  Adult dLck-Cre x Tgfbr2fl/fl mice showed no signs of 
autoimmunity, except when lymphopenia was induced (Zhang and Bevan 2012).  Yet  more recently, 
conditional deletion of Tgfbr2 was obtained by crossing to OX40-Cre mice.  This OX40-Cre 
promoter restricts deletion to activated peripheral T cells.  In this case, autoimmunity was observed 
indicating that activated T cells are indeed kept in check by  TGF-β in periphery  (Ishigame et al. 
2013).  
The importance of TGF-β signalling in Tregs was also closely  analysed since TGF-β signals are 
crucial for Treg differentiation. An absence of Tregs in Tgfb1-/- mice could explain the 
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autoimmunity phenotype.  Analysis of thymic Foxp3+ population in Tgfb1-/-, in CD4-dnTgfbr2 and 
CD4-Cre x Tgfbr2fl/fl mice revealed that this subset of CD4+T cells had normal (or increased) 
frequencies (Fahlen et al. 2005, Li et al. 2006, Marie et al. 2006).  However, in spleens and lymph 
nodes, Tregs were found to be markedly  reduced.  Theses results suggested that, while TGF-β 
signalling is not required for Foxp3+ Treg development in the thymus, it  is on the contrary essential 
for the maintenance of this subset in the periphery (Li et al. 2006, Marie et al. 2006). However, 
subsequent studies have questioned these observations, and found out that TGF-β was supporting 
the early  stages of Foxp3+ Tregs thymic development, notably  by antagonising thymic negative 
selection (Liu et al. 2008, Ouyang et al. 2010).  
2.4.3. Other roles of TGF-β in T cell differentiation and function
In addition to its role in maintaining tolerance by restricting T cell activation, TGF-β was shown to 
directly  impair Th1 and Th2 differentiation by  suppressing the lineage-defining transcription factors 
T-bet  and GATA-3, respectively (Li et al. 2006, Marie et al. 2006). However, the molecular 
mechanism behind this effect is still unclear.  
In vitro studies revealed that TGF-β diminished the CD8+T cell cytolytic activity by  decreasing the 
production of cytolysis effector molecules (Thomas and Massague 2005). Since activated Cytotoxic 
T Lymphocytes (CTLs) are predominantly  responsible for antigen-specific clearance of tumor cells, 
this role of TGF-β is of particular interest in the context of our research.  The inhibitory effects of 
TGF-β on CTLs was also shown in vivo by studies revealing that dnTGFβRII expression in CD8+T 
cells or treatment with a soluble TGFβRII potentiate immune responses against transplantable 
tumors (Gorelik and Flavell 2001, Thomas and Massague 2005).  Recently, the group of M. Li 
showed, that TGF-β negatively regulates CD8+ T cell responses by using a TRansgenic 
Adenocarcinoma of Mouse Prostate (TRAMP) mice model (Donkor et al. 2011).  Despite profound 
T cell infiltration into prostate tumours that develop in those mice, T cells cannot control tumour 
development.  However, TRAMP mice with dnTGFβRII expressing CD8+ T cells exhibit tumor 
protection, confirming that TGF-β signals in CD8+ T cells inhibit their function (Donkor et al. 2011, 
Oh and Li 2013).  To determine the importance of Treg-derived TGF-β in the inhibition of CD8+ T 
cell activity, the same group  crossed TRAMP with Foxp3-Cre x Tgfb1fl/n mice.  Those mice develop 
tumours similarly as the TRAMP mice, suggesting that Tregs are not the main source of TGF-β1 
involved in CD8+ T cell inhibition in these tumours (Donkor et al. 2011).  As stated above, one can 
not exclude that tumour infiltrating-Tregs activate latent TGF-β produced by other cell types (T 
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cells and tumor cells) to exert  suppressive function on infiltrating CD8+ T cells.  The authors 
additionally showed by crossing CD4-Cre x Tgfb1fl/n with TRAMP mice, that T cell-derived TGF-
β1 is crucial for anti-tumour response inhibition since tumour development is inhibited in those 
mice.  
When acting in combination with pro-inflammatory cytokines like IL-6, IL-1β, and IL-21, TGF-β 
can also induce Th17 differentiation in vitro.  Th17 cells are pro-inflammatory  T cells characterised 
by the production of IL-17 and the expression of the transcription factor RORγT.  In vivo, mice 
lacking TGFβRII on T cells have reduced numbers of Th17 cells. These findings highlight a 
fundamental role for TGF-β in Th17 differentiation and thus in enhancing pro-inflammatory T cell 
responses (Mangan et al. 2006, Veldhoen et al. 2006, Travis and Sheppard 2014).  
Finally, in vitro stimulation of murine peripheral CD4+CD25- naive T cells in the presence of TGF-
β1 converts T cells into CD4+CD25+Foxp3+ T cells.  Those cells are called induced Tregs (iTregs) 
as opposed to thymic derived Tregs (tTregs). In mice, iTregs were shown to display 
immunosuppressive functions in vivo and in vitro. Distinction between iTregs and tTregs is however 
not clear in humans (Luo and Li 2013).
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As stated earlier, work by our group showed that human Tregs, but not other T cell types, produce 
active form of TGF-β.  We also showed that human Tregs suppress the proliferation of the T cells in 
vitro through this production of active TGF-β.  Although the role played by Treg-derived TGF-β in 
suppression by  murine Tregs is not clear yet, TGF-β production may  be important for suppression 
by human Tregs.  The mechanisms by  which human Tregs activate latent TGF-β, and as for that of 
murine Tregs were not previously known.  The following chapter describes how transmembrane 
protein GARP was shown to play a role in this process.
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3. GARP, a transmembrane protein expressed by activated 
human Tregs
3.1. Structure of GARP (or LRRC32)
Glycoprotein A Repetition Predominant (GARP), also called Leucine Rich Repeat Containing 
Protein 32 (LRRC32), is a type I transmembrane protein of 662 amino acids. Its cytoplasmic 
portion comprises only  15 amino acids. Its large extracellular portion contains 20 leucine rich 
repeats (LRR), which are structural motifs of 20-30 amino acids with a characteristic repetitive 
sequence rich in leucines (Chan et al. 2011).  
Proteins containing in their primary structure tandems of two or more LRR motifs form a 
superfamily of proteins found in all life forms, from viruses to eukaryotes (Kajava 1998, Bella et al. 
2008).  This family includes intracellular, extracellular and transmembrane proteins that contribute 
to various biological processes such as cell adhesion and signalling, platelet aggregation, neuronal 
development and immune responses (Bell et al. 2003, Bella et al. 2008).  Although their functions 
are diverse, LRR-containing proteins share structural similarities.  The first crystal structure of an 
LRR protein was published in 1993 by Kobe and Deisenhofer using porcine ribonuclease inhibitor. 
They  observed that the arrangements of α-helices and β-strands in each individual LRR resulted in a 
horseshoe-like tridimensional structure (Kobe and Deisenhofer 1993, Kobe and Deisenhofer 1995). 
The structures of all LRR proteins studied since then revealed that proteins with LRR architecture 
form curved solenoid structures (Kobe and Kajava 2001, Bella et al. 2008). The major function of 
this horseshoe architecture may be to provide frameworks for stable protein-protein interactions but 
only few direct structural information are available (Kobe and Kajava 2001).  Toll-like Receptors 
(TLRs) are an example of LRR-containing protein in the innate immune system. Extracellular 
domains of TLRs bind a variety  of Pathogen-Associated Molecular Patterns (PAMPs) from bacteria, 
viruses and fungi. Although the structure of TLR extracellular domains have not been solved, their 
structure could be predicted according to the similarities between their amino acid sequences with 
those of known LRR structures. TLRs were suggested to have horseshoe-shaped structures 
providing large binding surfaces to allow PAMP recognition (Bell et al. 2003).
Wang and colleagues studied the structure of soluble GARP by electron microscopy  analysis.  They 
observed that GARP displays as expected a horseshoe shape (Wang et al. 2012).
Introduction________________________________________________________________________________________________
39
3.2. GARP expression pattern and regulation
As assessed by Northern Blot, GARP mRNA is found in many human tissues including placenta, 
lung, kidney, and to a lesser extent heart, liver, skeletal muscle and pancreas (Ollendorff et al. 
1994).  Wang et al. were the first to show preferential GARP expression in Tregs.  Our group 
confirmed this in Treg clones, which express 100-fold more GARP mRNA than Th clones.  GARP 
levels increase rapidly upon TCR stimulation in Treg clones, and return to resting levels after 24 
hours (Stockis et al. 2009b). Despite high mRNA levels in resting Tregs, GARP protein was only 
detected in activated Tregs and was completely  absent in stimulated or resting Th cells (Stockis et 
al. 2009b). Emilie Gauthy in our lab showed that GARP expression is regulated post-
transcriptionally  by miRNAs in T cells (Gauthy  et al. 2013). Zhou and co-workers also reported 
that microRNA miR143-3p targets GARP mRNA in CD4+CD25+ human T cells (Zhou et al. 2013).  
GARP protein is detected on the surface of human Tregs 24 to 72 hours after TCR stimulation 
(Wang et al. 2008, Probst-Kepper et al. 2009, Tran et al. 2009, Stockis et al. 2009b). It was 
therefore proposed that GARP could play a role in Treg function.  
3.3. Functions of GARP in Tregs
Soon after its identification as a Treg-specific surface protein, GARP was shown to serve as a 
presenting receptor for latent TGF-β1 at the cell surface (Tran et al. 2009, Stockis et al. 2009b). 
Tregs, but not other T cells, were known to bind latent TGF-β on their surface upon TCR 
stimulation.  Our group, and others, reported that ectopic expression of GARP in non-Treg T cells 
conferred the ability to present latent  TGF-β at the cell surface (Tran et al. 2009, Stockis et al. 
2009b).  Conversely, silencing of GARP in human Tregs reduced surface latent TGF-β1 at their 
surface (Tran et al. 2009).  Interactions between GARP and latent TGF-β1 were shown by co-
immunoprecipitation in Treg cells, and confirmed in pull-down experiments with recombinant 
soluble GARP and latent TGF-β1 (Stockis et al. 2009b). The structural view of this complex 
obtained by  electron microscopy analysis of soluble GARP and pro-TGF-β1 revealed that GARP 
and TGF-β1 are closely associated (Wang et al. 2012).
Recently, T. Springer’s group and our group showed that GARP is covalently bound to latent TGF-
β1 through disulphide linkage (Wang et al. 2012, Gauthy  et al. 2013).  Disulphide bounds involve 
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Cys33 in the LAP monomers and Cys211 and Cys350 in the GARP molecule.  GARP therefore 
binds the same Cys33 as LTBPs.  It is of note that Tregs do not appear to express LTBPs (our 
unpublished data).  But in transfected cells, GARP outcompetes LTBP for latent TGF-β1 binding 
(Wang et al. 2012).  It was suggested that GARP could function as an anchor for latent TGF-β at  the 
surface of Tregs, in a manner similar to LTBPs anchoring latent TGF-β in the extracellular matrix 
(Wang et al. 2012).  
Using human Th cells transduced with GARP, we also showed that GARP favors the cleavage of 
pro-TGF-β1 by FURIN (Gauthy et al. 2013).  No increase in FURIN expression or activity was 
detected upon transduction of GARP, and no interaction between GARP and FURIN could be 
evidenced.  The mechanism by which GARP increases latent TGF-β production by increasing 
cleavage of its precursor remains therefore unknown.  As a consequence of increased latent TGF-β 
production in the presence of GARP, we also observed increased secretion of the latent cytokine in 
GARP-transduced T cells (Gauthy  et al. 2013).  Interestingly, we found that latent TGF-β that is 
secreted by GARP-expressing T cells is secreted as complexes in which it is still disulphide linked 
to GARP.  Secretion of GARP/latent TGF-β complexes most likely occurs through shedding of 
surface GARP/TGF-β1 complex.  Release of GARP/latent  TGF-β1 complexes was also observed in 
stimulated human Tregs which naturally  express GARP.  The majority of latent TGF-β secreted by 
Tregs is associated to GARP.  Secretion of GARP/latent TGF-β complexes however, seems to be 
restricted to T lymphocytes: 293T cells transiently transfected with GARP and TGF-β1 do not 
release complexes in their supernatants although they  do present GARP and latent TGF-β1 at their 
surface (Gauthy  et al. 2013).  We still don’t know which protease, if any, mediates this T cell-
specific release of soluble GARP/TGF-β1 complexes.
Based on the above, it appears that GARP controls processing and secretion of latent TGF-β by 
human Tregs. But does it contribute in any way to the regulation of the immune suppressive 
function of these cells?  This question was addressed by several groups.   Wang et al. and Tran et al. 
showed that silencing GARP with siRNAs in human Tregs led to a moderate but significant 
decrease of their suppressive activity  in vitro (Tran et al. 2009, Wang et al. 2009).  These data are in 
line with the hypothesis that GARP, through presentation of latent TGF-β at the surface of Tregs 
may contribute to Treg suppression. In contradiction with these findings however is the data 
provided by the group  of E. Shevach using Tregs from CD4-Cre x Garpfl/fl mice (Edwards et al. 
2013). These mice develop normally to adulthood, without any signs of autoimmunity. This 
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indicates that Garp expression in mouse Tregs in vivo is not required for immune homeostasis and 
the maintenance of tolerance.  In addition, Garp-deficient Tregs were as competent as WT Tregs in 
suppressing the proliferation of target  cells in vitro (Edwards et al. 2013).  Therefore, whether or 
not  Garp contributes to the immune suppressive activity of murine Tregs remains an open question.
Our group addressed the question of the role of GARP in suppression by human Tregs.  We know 
that suppression by human Treg clones is cell-cell contact  dependent, and that it is also dependent 
on the production of active TGF-β by the Treg cells (Stockis et al. 2009a).  Thus, we hypothesise 
that GARP, through presentation of latent TGF-β at the Treg surface, may be required for the 
activation of the cytokine by  Tregs, and hence required for the immune suppressive function of 
these cells.  To test this hypothesis, we generated a series of monoclonal antibodies (mAbs) against 
human GARP (Cuende et al. manuscript submitted).  Two of 31 anti-GARP mAbs were able to 
block the production of active TGF-β1 by human Tregs.  Interestingly, we could show that  the two 
blocking anti-GARP mAbs recognise an epitope that requires GARP amino acids 137-139 in 
GARP/latent TGF-β complexes.  All other non-blocking anti-GARP mAbs recognise other epitopes. 
In addition to blocking active TGF-β production by human Tregs, the two blocking anti-GARP 
mAbs also inhibit partially  the ability  of Tregs to suppress the proliferation of target cells in vitro. 
Finally, we tested the blocking mAbs in vivo.  Because our anti-human GARP mAbs do not cross-
react against mouse Garp, we had to resort to a model of xenogeneic graft-versus-host disease 
(xGVHD) in (NOD/Scid/Il2rg-/-) NSG mice. NSG mice are profoundly immuno-incompetent. 
Transfer of human PBMCs in NSG mice leads to efficient engraftment and proliferation of human 
T cells.  A few weeks after transfer, severe xGVHD develops, due to the activity of human T cells 
against murine tissues.  xGVHD can be delayed if autologous Tregs are co-transferred with the 
PBMCs. Tregs suppress xenogeneic T cell activity in this model. This provided us with the 
opportunity to test  the ability of blocking anti-human GARP to inhibit human Treg function in vivo 
(Cuende et al. manuscript submitted). We could clearly demonstrate that blocking anti-GARP mAbs 
aggravated xGVHD in mice grafted with PBMCs and Tregs.  Importantly, non-blocking anti-
GARP mAbs had no effect.  These results show that GARP is required for active TGF-β production 
by human Tregs and contributes to the immune suppressive function of these cells in vivo.
To summarise the above, we propose the following roles of GARP in the production of TGF-β by 
human Tregs (Figure 5).  After the removal of the signal peptide in the ER, newly  synthesised TGF-
β1 monomers associate to form the pro-TGF-β1 dimer. Pro-TGF-β1 associates to GARP through 
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the formation of disulphide bounds between LAP and GARP. Co-immunoprecipitation experiments 
indicate indeed that pro-TGF-β is already bond to GARP in Tregs. This association favours 
cleavage of pro-TGF-β1 by  Furin, leading to the formation of latent TGF-β1, which remains 
associated to GARP. GARP/latent TGF-β1 complexes translocate to the Treg surface. There, 
GARP/latent TGF-β1 complexes can be shed from the membrane through an unknown mechanism 
and secreted in the Treg supernatant. The function of soluble GARP/latent TGF-β1 complexes 
secreted by  Tregs is not known.  In response to TCR stimulation, latent TGF-β1 bound to GARP at 
the Treg surface can be activated. Active TGF-β1 production by Tregs acts in both autocrine manner 
on Tregs themselves, but also in a paracrine manner on neighbouring T cells.  The paracrine activity 
of active TGF-β1 produced by  human Tregs contributes to their immune suppressive function. 
This can be blocked with anti-GARP mAbs (Cuende et al. manuscript submitted).
It must be noted that GARP is not required for pro-TGF-β1 cleavage and latent TGF-β1 secretion. 
This occurs also in cells that do not express GARP.  Forced expression of GARP in non-Treg cells 
(293T cells or Th lymphocytes) increases pro-TGF-β1 cleavage and is sufficient to induce the 
presentation of GARP/latent  TGF-β1 complexes on the cell surface.  Interestingly, secretion of 
soluble GARP/latent TGF-β1 complexes occurs only  when GARP is in T cells, either in Tregs or in 
Th cells transduced with GARP.  293T cells transfected with GARP do not secrete GARP/latent 
TGF-β1 complexes.  This appears to represent a T-cell specific mechanism, although we do not 
know the function of these secreted complexes.  But more importantly, forced expression of GARP 
in non-Treg cells is not sufficient to induce active TGF-β1 production.  This is true in 293T cells, 
but also in Th cells.
We hypothesised therefore that production of active TGF-β1 in Tregs, requires not only  GARP, but 
also other yet unknown protein partners expressed in Tregs but not in Th cells. The aim of my thesis 
work was to identify proteins associated with GARP that contribute to the activation of latent  TGF-
β1 in human Tregs.  To achieve our objectives, we used two different approaches to identify  Treg 
proteins interacting with GARP.  In the next chapter, I will present an overview of the multiple 
techniques available to study protein-protein interactions. 
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Figure 5. Schematic representation of TGF-β1 production in Tregs.
TGF-β1 is synthesised as a pre-pro-protein. In the ER, the signal peptide is cleaved and two molecules associate to form 
the pro-TGF-β1 dimer.  A minority of pro-TGF-β1 is cleaved by furin and secreted as latent TGF-β1 free of GARP, 
while majority of pro-TGF-β1 disulphide links GARP in the ER. This association favours cleavage of pro-TGF-β1 by 
Furin leading to the formation of latent TGF-β1, which remains associated to GARP. GARP/latent TGF-β1 complexes 
translocate to the surface of Tregs where they are shedded (unknown mechanism). Upon TCR stimulation, latent TGF-
β1 can be activated. Active TGF-β1 released from the LAP can act on the Treg itself (autocrine signalling) or on 
neighbouring cells (paracrine signalling). 
GARP
LAP
cytosol
nucleus
secretory 
pathway
latent TGF-β1 
secretion
Activation
furin cleavage
TGFB1 gene
Shedding ?
mature 
TGF-β1
active 
TGF-β1
complex 
translocation
Transcription
TGFB1 
mRNA
Translation
pro-TGF-β1
latent TGF-β1
pre-pro-TGF-β1
Secretion of 
GARP/latent TGF-β1 
complexes
Role of soluble 
GARP/latent TGF-β1 
complexes?
Introduction________________________________________________________________________________________________
44
4. How to study protein-protein interactions?
Protein-protein interactions (PPIs) are crucial for cellular function and dysfunction and large efforts 
are therefore invested in their identification and analysis.  Over the past 25 years, many techniques 
to study PPI were developed that can be applied to a large variety of proteins with different 
structures and functions (Auerbach et al. 2002, Suter et al. 2006, Suter et al. 2008).  A given PPI is 
characterised by the type of bonds occurring between the protein partners, and thus by its stability. 
Strong interactions occurring between proteins associated through a covalent bond are called 
«stable» PPIs. However, «stable» interactions represent a minority of PPIs. Examples of stable 
interaction include the association between two pro-TGF-β molecules through disulphide links, or 
the association of GARP with LAP. The majority  of PPIs are transient interactions between partners 
that are not covalently  associated. These interactions are called «labile» PPIs (Westermarck et al. 
2013, Ngounou Wetie et al. 2014). Dimerisation between phosphorylated SMAD2 and SMAD3 and 
complex formation with SMAD4 in response to TGF-β signals are examples of «labile» 
interactions. Notably, some PPIs result  from a combination of stable and labile interactions. This is 
the case for example GARP and latent TGF-β complexes in which GARP and LAP are linked 
through disulphide bonds and in which mature TGF-β dimers are non-covalently associated to LAP 
dimers (Wang et al. 2012, Gauthy et al. 2013).  According to the stability  of the interactions, some 
techniques are more appropriate than others.  
Because of the wide variety of systems that have been developed in the past  decades, it  is difficult 
to present an exhaustive list  of the techniques.  It is important to note that a large field of research 
on PPI is based on biophysical techniques (X-Ray crystallography  or Nuclear Magnetic 
Resonance), and «in-silico» methods.  These techniques will not be described here but are reviewed 
in Wetie et al. and Rao et al. (Ngounou Wetie et al. 2014, Rao et al. 2014).  Different classifications 
of the PPI techniques have been used in the literature. I will distinguish «in-cell» methods, which 
detect interactions in an intact cell system (yeasts or mammalian cells), from biochemical methods, 
which detect interactions in cell-free systems or after cell lysis.
Introduction________________________________________________________________________________________________
45
4.1 PPI detection by «in-cell» methods
4.1.1 Yeast Two-Hybrid systems
(i) Classical Y2H.  The Yeast Two-Hybrid (Y2H) system was originally  described by Fields and 
Song in 1989 (Fields and Song 1989).  They developed a genetic system to detect PPIs in a cellular 
setting taking advantage of the yeast transcriptional machinery.  Their approach was based on the 
finding that the GAL4 transcription factor (TF) can be separated into two domains: the DNA 
Binding Domain (DBD) and the Activation Domain (AD).  These two fragments do not associate 
spontaneously  and are inactive when expressed individually in the absence of other in yeast.  To test 
an interaction between two proteins, the first protein, called the bait, is fused to the DBD, and the 
second protein, called the prey, is fused to the AD.  When those two hybrid proteins are expressed 
in yeast, DBD and AD are brought closely to form an active TF only if bait  and prey interact with 
each other (Figure 6a).  To measure transcriptional activity, reporter genes under the control of an 
Upstream Activating Sequence (UAS) are inserted in the yeast genome. These reporter genes, are 
transcribed only  if the prey interacts with the bait that is bound to the UAS through the DBD. 
Originally, Fields and Song used a lacZ reporter gene allowing to use β-galactosidase activity  as a 
sensor of the interaction between two proteins tested.  Now, auxotrophic genes (HIS3, ADE2...) are 
used as reporters.  They  allow yeasts in which an interaction between bait and prey occurs to grow 
on selective media.  
The Y2H system is suitable to test the existence of interactions between two known proteins, but it 
can also also serve to screen cDNA libraries to identify new partners of a bait of interest. Yeasts in 
which an interaction occurs grow on minimal media and the preys expressed in those yeasts can be 
identified by  DNA sequencing.  Y2H has been widely used during the last decades.  For example, 
many studies used the Y2H system to identify proteins interacting with the SMADs. The 
identification of SMAD partners with this method allowed for a better understanding of the TGF-β 
signalling pathway and its regulation in various cell types (Liberati et al. 1999, Liberati et al. 2001, 
Komuro et al. 2004, Long et al. 2004).  
The Y2H technique is a powerful tool for PPI study.  It has the advantages to be cheap, rapid and 
easy to implement.  Moreover, it is very sensitive and suited to test  labile interactions.  However, 
this method faces several limitations.  One first obvious limitation is that baits, fused to DBD, must 
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not activate transcription on their own.   This would indeed lead to activation of the reporter genes 
and thus make the selection of yeasts impossible.  Some «tricks» have been set-up to avoid 
excessive auto-activation of reporter genes (Auerbach et al. 2002).  When using HIS3 reporter gene, 
growth medium can be supplemented with 3-aminotriazole, a competitive inhibitor of the HIS3 
gene product.  This has been shown to lower background due to the self-activation of the bait-DBD 
fusion.  Another trick is to clone the bait-DBD coding sequence downstream of a weaker promoter 
to decrease the number of copies of the fusion protein.  A second major limitation is that bait and 
prey fusion proteins need to be present, and correctly folded in nucleus of yeasts to induce 
transcriptional activity.  This means that the classical Y2H method is not applicable to the analysis 
of proteins with hydrophobic sequences, typically found in transmembrane proteins for example. 
To circumvent this problem, membrane proteins can be expressed as truncated forms, to facilitate 
targeting to the nucleus.  A third problem is that some interactions between two partner proteins 
require the presence of additional partner(s). When studying non-yeast proteins, this can be 
problematic as the fusion proteins are not expressed in the presence of other proteins that may be 
essential for the interaction to occur.  Although some tricks exist to circumvent these limitations, 
these are not always successful.  Therefore, alternative approaches have been developed (Table 1).  
(ii) RNA polymerase III based system.   Transcription of most of the genes coding for proteins is 
ensured by the RNA polymerase II enzyme (pol II).  Only a few genes are transcribed with RNA 
polymerase III (pol III).  Among these is gene SNR6.  This gene codes for an essential small nuclear 
RNA (snRNA) and its transcription is induced by the binding of Transcription Factor III C (TFIIIC) 
on an upstream DNA sequence called «B-Block».  Marsolier and colleagues showed that when B-
Block is replaced by a GAL4 UAS, a truncated version of TFIIIC (t-138) associated to GAL4 DBD 
can recruit pol III and induce SNR6 transcription (Marsolier et al. 1997).  This finding led to the 
development of a two-hybrid system in which the bait is fused to t138 protein fragment and the prey 
is fused to GAL4 DBD.  Interaction between bait and prey, induces pol III recruitment to the snr6 
reporter, transcription and production of the snRNA and yeast survival (Figure 6b).  This system has 
the advantage to detect interactions with reporter genes that are synthesised using pol III, therefore 
allowing to use transcription factors as baits, as long as these function by recruiting  pol II.  It was 
used in 2001 to screen for new BRCA1 partners in a cDNA library from mouse embryonic cDNA. 
The authors took advantage of a yeast reporter strain bearing a mutation in the endogenous SNR6 
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gene, making yeasts sensitive to temperature (ts snRNA yeasts).  At 37°C, only  yeasts transcribing 
the reporter WT SNR6 gene are able to grow (Petrascheck et al. 2001). 
(iii) Yeast three-hybrid.   To test  PPI in which more than two protein partners are involved, a system 
referred to as the Yeast Three Hybrid system (Y3H) was developed (Figure 6c).  This system was 
first designed to study protein-RNA interactions (Sengupta et al. 1999, Zhang et al. 1999). 
However it was extended to the study of additional protein partners and to small molecules. In the 
case of additional proteins mediating an interaction between bait and prey, yeasts are transformed 
with an additional vector coding for a third «non-fusion» protein (Drees 1999).  Of course, the 
identity of the «intermediate» partner must be known a priori in this system.
Figure 6.  Yeast two-hybrid systems detecting PPI in the nuclei of yeasts.  
(a) Classical yeast two hybrid  (Y2H).  The bait (B) is fused to the DNA Binding Domain (DBD) of GAL4 while the 
prey (P) is fused to the activation domain (AD) of GAL4.  Interaction between Bait and Prey allows polymerase II (pol 
II) recruitment and gene transcription resulting in yeast growth on minimal media.  (b) RNA-pol III based system.  The 
bait is fused to GAL4 DBD and prey is fused to t-138, a portion of TFIIIC allowing the recruitment of pol III. Yeasts  in 
which SNR6 is produced survive at 36°C.  (c) Yeast three-hybrid system (Y3H). Adaptation of the Y2H system to allow 
interaction between bait and prey mediated by a third partner (X).  (d)  Reverse two-hybrid.  Application of the Y2H to 
identify molecules disrupting interactions.   Yeast in which interaction is prevented grow on a medium supplemented 
with 5-FOA. 
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(iv) Reverse two-hybrid system.  This is an application of the Y2H system to identify molecules that 
interrupt PPI.  The group of Marc Vidal used the URA3 reporter to allow negative selection (Vidal 
et al. 1996).  In yeasts in which bait and prey interacts, the URA3 gene is transcribed.  In the 
presence of 5-FOA (5-Fluoroorotic acid), the URA3 enzyme modifies 5-FOA into a toxic product 
and yeast die. However, when the bait/prey interaction is disrupted by a protein or another 
molecule, the URA3 reporter is not transcribed and yeast grow as 5-FOA remains in its non-toxic 
form (Figure 6d).  This technique allows to screen for small molecules, supplemented in the yeast 
growth medium, or for proteins introduced by transformation that disrupt interaction. This 
application is particularly interesting for the identification of new drugs targeting PPIs.
(v) The SOS and Ras Recruitment Systems.  The SOS Recruitment System (SRS) and the Ras 
Recruiment System (RRS) were developed in the late 90s by Aronheim and colleagues (Aronheim 
et al. 1997, Broder et al. 1998).  In the Ras pathway, binding of growth factors induces receptors 
dimerisation, trans-phosphorylation on tyrosine residues and recruitment via adaptors, of a Guanyl 
Exchanging Factor (GEF) that activates membrane-anchored Ras by exchanging GDP by GTP. 
Activated Ras triggers a signalling cascade, which results in cell growth.  In yeast, Ras is activated 
by a GEF called cdc25. The SRS and RRS exploits a yeast strain harbouring a temperature sensitive 
(ts) cdc25-2 allele; the cdc25-2 yeast  strain is able to grow at 25°C but not at 36°C.  The authors 
found that the human GEF called SOS (hSOS) can rescue yeast harbouring a ts cdc25, allowing 
them to grow at 36°C.  To exert its function, hSOS needs to be located at the plasma membrane. 
This system allows to test for interactions between a cytosolic bait fused to hSOS, and a membrane-
anchored prey.  If the bait interacts with the prey, hSOS is recruited at the cell membrane and yeasts 
grow at 36°C (Figure 7a).  
With this system, interaction occurs at  the cell membrane and targeting to the nucleus is avoided. 
Moreover, the sensor of PPI is not the transcription of reporter genes but the activation of signalling 
pathway in the cytosol.  Thus, SRS is suited to test interactions with baits that are transcriptional 
activators.  Originally, the SRS system was used for the identification of interactions in the AP-1 
family of transcription factors (Aronheim et al. 1997).  Apart from this advantage, the technique has 
the limitation that baits must be cytosolic proteins: with membrane baits, hSOS will be located at 
the membrane in the absence of interaction with a prey.  In addition, when prey  cDNA libraries are 
screened, mammalian Ras (mRas) or GEF represent very frequent false positives.  
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Figure 7.  Ras pathway-based yeast two-hybrid systems.  
These systems use a cdc25-2 mutant yeast unable to activate the Ras pathway at 36°C. (a) SOS-Recruitment System 
(SRS).  The bait (B) fused to hSOS is recruited to the cell membrane through its interaction with the membrane 
anchored prey (P).   At the cell membrane it exchanges GDP to GTP on yeast Ras (yRas) and activates yeast growth at 
36°C (b) Ras Recruitment system (RRS). Constitutively active mutant mutRas, bypassing the need to activate yRas, is 
recruited at the cell membrane through interaction with anchored preys.  Yeast are allowed to grow at 36°C. (c) Reverse 
Ras Recruitment system (reverse RRS). The prey is fused to mutRas and recruited at the cell membrane through 
interaction with the integral membrane bait.  Yeast are allowed to grow at 36°C.
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To improve their system, the inventors suggested to express a mammalian GTPase-activating 
protein (mGAP) that removes GTP from mRas but  not from yeast  Ras (Aronheim 1997). This 
allowed to decrease the number of false positives identified by SRS but  not significantly enough in 
many instances.  
The authors then designed an alternative technique called the RRS (Broder et al. 1998).  In this 
system, the bait is fused to a mutated Ras (mutRas) that  is constitutively active and prevented to 
anchor at the cell membrane.  This «soluble mutRas» substitutes yRas (yeast Ras), but requires 
membrane localisation to function (Figure 7b).  As for the SRS, yeast in which bait  and prey are 
expressed grow only if mutRas is recruited at the cellular membrane through its interaction with a 
membrane-anchored prey.  
To be suited for the study of interaction with a bait that is an integral membrane protein, the group 
of Aronheim proposed a «reverse RRS».  In this reverse system, the bait is a membrane protein and 
the preys are fused to the mutRas (Hubsman et al. 2001, Kohler and Muller 2003).  This is thus 
suited for the use of membrane baits but means that preys have to interact with the cytosolic portion 
of the membrane bait to be detected (Figure 7c). 
(vi) Split-Ubiquitin System.  This technique was first described by Johnsson and Varshavsky  in 
1994 (Johnsson and Varshavsky 1994). The ubiquitins are small proteins that are attached to other 
proteins by ubiquitin ligases.  They  target proteins to which they bind for degradation by  the 
proteasome. During degradation, ubiquitins are detached from proteins to which they were 
transferred by  Ubiquitin Specific Proteases (UBPs) and recycled.  Johnsson and Varshavsky found 
that ubiquitins can be split into two fragments, the C-terminal part (CUB) and the N-terminal part 
(NUB), and that these fragments alone are not recognised by UBPs (Johnsson and Varshavsky 
1994).  Spontaneous reassembly of CUB and NUB can occur if the two fragments are expressed 
together, but a mutation in NUB prevents this spontaneous reassembly.  Mutated NUB is called 
NUBG.  The authors then developed a two-hybrid system in which the bait is fused to CUB and the 
prey is fused to NUBG.  If bait  and prey interact when expressed in yeast, CUB and NUBG are 
brought in close proximity, and reform a native-like ubiquitin that is recognised by yeast UBPs.  To 
report this interaction in yeast, different systems have been designed and include the rUra3 and the 
transactivation systems.
Introduction________________________________________________________________________________________________
52
ER
nucleus
Reporter genes
Reporter transcription
ER
active rUra3 
no growth in medium 
with 5-FOA
B P
CU
B
NUBG
rUra3
UBPs
rUra3 release and 
degradation
growth in medium 
with 5-FOA
B P
CU
B
NUBG
rUra3
nucleus
cytoplasm
CU
B
NUBG
UBPs
B P
CU
B
NUBG
B P
cytoplasm
Ost4BCUB
PNUBG
Ost4
UBPs
BCUB
PNUBG
(a)
(b)
(c)
ER
nucleus
cytoplasm
Nuclear translocation
VP16
LexA
VP16
LexA
VP16
LexA
VP16
LexA
VP16
LexA
VP16
LexA
Reporter genes
Reporter transcription
Nuclear translocation
Introduction________________________________________________________________________________________________
53
Figure 8. Split-ubiquitin systems in yeast.  
Two fragments of ubiquitin (CUB and NUBG) are fused to Bait (B) and prey (P) respectively.  When CUB and NUBG 
are brought in close proximity due to a bait-prey interaction,  yeasts UBiquitin specific Proteases (UBPs) cleave a 
peptide link between the reformed ubiquitin and the reporter molecule. (a) When rUra3 is used as a reporter system, 
interaction induces release of a modified Ura3 enzyme (rUra3), which is rapidly degraded upon release from the bait. 
Bait-prey interaction is reported by ability to grow in the presence of 5-FOA. (b) Membrane Yeast Two-Hybrid 
(MYTH) system uses LexA-VP16 hybrid TF to report interaction using reporter genes in the yeast genome.  Bait-prey 
interaction occurs at the cell membrane where the TF is retained.  (c) Cytosolic Y2H.  Modified split ubiquitin system 
with LexA-VP16 as a reporter adapted for to test interactions between cytosolic proteins.  Bait is retained at the ER 
membrane through a fusion to Ost4 ER membrane protein.
In the rUra3 system, the bait  is fused to CUB which is itself fused to the rUra3 protein (Bait-CUB-
rUra3).  The Ura3 protein is an enzyme that converts 5-FOA into a toxic metabolite. The rUra3 
protein is a modified unstable Ura3 enzyme.  When rUra3 protein is linked to CUB, it is stabilised, 
5-FOA supplemented in the medium is degraded into its toxic metabolites, and yeasts do not grow 
(Dunnwald et al. 1999, Dirnberger et al. 2008). When a bait-prey interaction occurs, the CUB-
NUBG are recognised by UBPs, which cleave the link between CUB and rUra3.  Release of rUra3 
from CUB results in rapid degradation of the enzyme, allowing yeasts to grow on media containing 
with 5-FOA (Figure 8a).  Here again, as the reporter of PPI is not based on gene transcription, the 
interaction between bait and prey can occur anywhere in the cell and is thus applicable to almost all 
protein types, i.e. cytosolic, nuclear and membrane proteins.  
In the transactivation system, the sensor of PPI is the transcription of reporter genes. The bait is a 
membrane protein and is fused to CUB, itself fused to a LexA-VP16 hybrid transcription factor 
(Stagljar 1998). Due to its association with a membrane protein, the hybrid TF cannot reach the 
nucleus and bind to DNA and is thus unable to exert transcriptional activity. When bait and prey 
interact, the UBPs cleave the link between CUB and LexA-VP16, allowing the TF to migrate to the 
nucleus and activate the transcription of reporter genes (Figure 8b). Like for the classical Y2H, 
auxotrophic markers and LacZ reporter can be used. For this system to work, CUB and NUBG have 
to be both in the cytosol. The topology of bait and prey and the extremity to which CUB and NUBG 
are fused is therefore of fundamental importance. This system has been termed «Membrane Yeast 
Two-Hybrid» (MYTH) because it is, compared to other Y2H systems, the only system that can test 
interactions between two membrane proteins (Johnsson and Varshavsky 1994). 
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Derived from this technique, an adapted Cytosolic Y2H (CytoY2H) was designed in 2007 (Figure 
8c). The authors propose to fuse the bait on one side to Ost4, a yeast membrane protein from the 
ER, and on the other side to CUB-LexA-VP16 (Mockli et al. 2007). This allows to use the split-
ubiquitin system with baits that are not membrane proteins.  Interestingly, baits with transcriptional 
activity can also be used in cytoY2H.
(vii) Screening for interactions between extracellular proteins. Among all the two-hybrid 
techniques described, none is suited to identify  interactions involving extracellular proteins. 
However, this group of proteins are particularly  interesting since they are easily  accessible targets in 
therapeutics. Proteins that are on the cell surface or secreted in the extracellular space are conducted 
through the secretory pathway (ER and Golgi apparatus), which provides an environment allowing 
correct folding, disulphide bond formation and glycosylation of the proteins (Wright et al. 2010).  It 
is thus necessary, when addressing interaction between these proteins, to be in a context close to 
their natural setting. Only one Y2H system was fitted for the study of secreted proteins: the 
SCreening for INteractions between EXtracellular Proteins (SCINEX-P), designed by Urech et al. 
in 2003 (Urech et al. 2003).  This assay takes advantage of the yeast Unfolded Protein Response 
(UPR).  Upon accumulation of misfolded proteins in the ER, a type I transmembrane yeast protein 
called Ire1p homodimerises in its N-terminal luminal part.  This induces association of the C-
terminal, cytosolic parts of Ire1p, and triggers a signalling cascade leading to Hac1p transcriptional 
activator synthesis. Hac1p binds to the Unfolded Protein Response Elements (UPRE) in the 
promoter of genes coding for chaperone proteins.  To study PPI, one bait and one prey, located in 
the ER, are fused to mutated cytosolic parts of Ire1p (Figure 10).  These mutants complement each 
other to reach nearly  100% of WT activity  but are inactive as monomers. If bait and prey interact in 
the ER, the Ire1p mutated fragments dimerise and induce UPR. For this assay, the yeast strain must 
harbour an inactivating mutation in the endogenous Ire1 gene, and an UPRE must be inserted in the 
promoter region of the reporter genes  (Urech et al. 2003, Pollock et al. 2004).  
Overall, the yeast two-hybrid techniques described above allow the detection of binary interactions 
between two candidate proteins. It is suited to assay transiently, weakly interacting partners. The 
corollary to the high sensitivity of these techniques is that when used in screening, they lead to large 
proportions of false positives. Moreover, due to the expression of proteins in an artificial system, 
the Y2H systems can fail to detect some interactions that  occur in a natural setting. To validate an 
interaction between two proteins, the use of alternative techniques might be required. 
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Figure 9. SCreening for INteractions between EXtracellular Proteins (SCINEX-P). 
Upon accumulation of misfolded proteins in the ER, yeast Ire1p proteins dimerise and induces a signalling cascade 
leading to Hac1p transcriptional activator synthesis.  Hac1p binds to the Unfolded Protein Response Elements (UPRE) 
in the promoter of genes coding for chaperone proteins.  In this system, Bait (B) and prey (P) are fused to mutated Irep1 
proteins so that dimerisation of Irep1 is dependent on association between bait and prey.  Once Irep1 mutated proteins 
are in close proximity, signalling cascade is active, Hac1p is induced and can bind to UPRE sequences to induce 
activation or reporter genes.  
4.1.2 Mammalian Two-Hybrid systems
A diverse series of mammalian two-hybrids have emerged over the past  decades (Table 1).  These 
systems were developed to evaluate interactions between proteins in a cellular system that is similar 
to the native cellular context of the assayed proteins. This is of particular interest for a subset of PPI 
in which adaptor molecules or protein modifications are required for an interaction. Additionally, 
the mammalian two-hybrids offer the possibility to determine spatio-temporal information about 
protein interactions. Indeed, PPI are dynamic, they  occur in some cell compartments, at  certain 
moments or under certain stimuli. Therefore the use of mammalian two-hybrid is better suited than 
the yeast systems (Remy and Michnick 1999, Remy and Michnick 2007, Lievens et al. 2009).
(i) Mammalian two-hybrid «sensu stricto».  The original Y2H system was adapted in mammalian 
cells and called the Mammalian two-hybrid (M2H).  Like in yeast, two hybrid proteins, a bait-DBD 
and a prey-AD, are expressed in mammalian cells and bait/prey  interactions are reported with a 
gene under the control of the reconstituted TF (Figure 10). This system, as for the original Y2H, 
detects protein interactions within the nucleus (Luo et al. 1997).  Classically, the DBD of GAL4 and 
the AD of the VP16 protein are used.  This system was for instance used to shed light on the 
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interaction between Smads (Smad 2 and 4) and CREB binding protein (CBP) upon TGF-β 
treatment (Topper et al. 1998).  In this paper, the authors transfected bait and prey  in Bovine Aortic 
Endothelial cells and reported the interaction using a luciferase reporter gene. 
Figure 10.  Mammalian two-hybrid systems sensu-stricto (M2H).  
Bait (B) and prey (P) are fused to DBD of GAL4 and VP16 transactivator factor respectively.   If bait and prey interact, 
reporter genes (often luciferase) is transcribed and activity is measured by light emission derived from luciferase 
substrate degradation.  Interaction is detected in the nuclei or mammalian cells.  
(ii) Protein-fragment Complementation Assay. A large family of two-hybrid systems in 
mammalian cells have been termed Protein-fragment Complementation Assay (PCA) (Remy and 
Michnick 2007, Kerppola 2008).  In theses systems, bait and prey are fused to fragments of a 
reporter molecule.  Alone, each fragment of the reporter has no activity. However, if bait and prey 
interact, the moieties of the reporter are brought in close proximity and the native molecule is 
reconstituted. The reporter molecule activity is recovered and generates a quantifiable signal 
(Figure 11).  Different reporter molecules have been used including β-galactosidase (Rossi et al. 
1997), β-lactamase (Galarneau et al. 2002, Wehrman et al. 2002), Dihydrofolate reductase (Pelletier 
et al. 1998, Remy and Michnick 1999), several luciferases (Paulmurugan et al. 2002, Paulmurugan 
and Gambhir 2003, Remy and Michnick 2006, Stefan et al. 2007) and fluorescent  proteins (Wilson 
et al. 2004, Kerppola 2008).  
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Interaction with PCA is reported with an enzymatic activity or fluorescence of the reporter 
molecule, meaning that the interaction can take place anywhere in the cell, and that this technique is 
suited to a wide variety of bait and preys. PCAs can be applied for pairwise interaction assays but, 
even though it is possible, theses techniques are less amenable than Y2H screens for high 
throughput analysis and identification of new interacting partners (Remy and Michnick 2007, 
Lievens et al. 2009).  
PCAs, with β-lactamase and Yellow Fluorescent Protein (YFP) as reporters, were used to shed light 
on a cross-talk between the insulin (PKB/Akt) and the TGF-β (Smad) signalling pathways.   It was 
shown that Smad3 directly  binds to PKB and that  this binding is modulated by  insulin and TGF-β 
(Remy  et al. 2004).  The advantage of using fluorescent reporters compared to enzymatic ones is 
that the signals emitted by the PPI can be tracked in the cell and localized in cell compartments. 
Moreover, compared to other complementation assays, addition of chromogenic or fluorogenic 
substrates is avoided since fluorescence emission is intrinsic to the complemented molecules.  The 
PCAs using fluorescent molecules (YFP, GFP...) have been termed Bimolecular Fluorescent 
Complementation (BiFC) (Kerppola 2008).
Another interesting application of the PCA is the detection of PPI occurring in living animals.  This 
was set up by  Luker and colleagues in 2004 using firefly luciferase complementation and the 
described interaction between the Rapamycin Binding domain (FRB) of mammalian target of 
rapamycin (mTor) and the FK506-binding protein 12 (FKBP).  They fused FRB to the N-terminal 
part of firefly  luciferase and FKBP to the C-terminal part of firefly luciferase (Luker et al. 2004). 
Here, to validate the in vivo model of PCA, 293T cells expressing the two fusion proteins were 
injected in mice.  After rapamycin injection, cells in which FRB and FKBP interact are detected via 
emission of bioluminescent signals. The possibilities emerging with such techniques are of huge 
interest especially in drug therapy development (Michnick et al. 2007).  
A particular PCA called «split-TEV» takes advantage of a protease produced by the Tobacco Etch 
Virus (TEV).  This system works as other PCA in the sense that the complementation of two 
fragments of the TEV protease leads to the reconstitution of an active enzyme.  However, the 
activity of the protease is measured by  the cleavage of a «TEV recognition sequence» and the 
subsequent release of a reporter protein.  The reporter protein can be a TF or a luciferase enzyme. 
This means that this system is irreversible and that the interaction will be reported, even if two 
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proteins interact  transiently  and the TEV protease is reconstituted even for a short  period of time 
(Wehr et al. 2008).  This technique has not yet been used for library screenings but it has been 
applied recently to the identification of siRNAs inhibiting a signalling pathway in Drosophila (Suter 
et al. 2008, Wehr et al. 2013).  
Figure 11.  Mammalian Protein-fragment Complementation Assays (PCAs).  
Bait (B) and prey (P) are fused to N-terminal and C-terminal fragments of reporter molecule respectively.  If Bait and 
prey interact, reporter activity is reconstituted.  Many different reporter molecules are used: Luciferase, β-galactosidase, 
β-lactamase, dihydrofolate reductase, fluorescent molecules, TEV protease.  Interactions can take place in any cell 
compartment.
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(iii) Mammalian protein-protein interaction trap.  The MAmmalian PPI trap (MAPPIT) system 
was designed by the group of Tavernier in 2001 (Eyckerman et al. 2001). They exploited the well 
described ligand-induced JAnus Kinase - Signal Transducer and Activator of Transcription (JAK-
STAT) signalling pathway to study PPI. A wide variety of cytokines activate the JAK-STAT 
pathway upon binding to their receptor.  In response to ligand binding, receptors dimerise, and a 
conformational change activates the associated JAKs.  Once activated, JAKs phosphorylate each 
other as well as the cytoplasmic domain of the receptor, and this enables STAT recruitment.  STATs 
are phosphorylated by JAKs, dimerise, and translocate in the nucleus to activate gene transcription 
(Staerk and Constantinescu 2012). In this PPI assay system, a bait is linked to a cytokine receptor 
harbouring a mutation preventing STAT binding. The prey is linked to the cytoplasmic portion of 
another cytokine receptor chain (gp130) containing an intact STAT recruitment site. The interaction 
between bait and prey  leads to signalling upon cognate ligand binding since the gp130-prey fusion 
complements the defect of the mutated receptor (Figure 12). Reporter genes such as luciferase are 
under the control of a STAT-dependent  promoter to report interaction. This technique is very 
sensitive because one bait-prey  interaction results in multiple activated STAT molecules, and this 
amplifies the reporter signal.  An important feature of the assay is also its dependence on ligand 
binding, which allows to control the condition in which the interaction is tested.  This system is 
only compatible with baits and preys that are cytoplasmic or nuclear proteins.  A Reverse MAPPIT 
system was also proposed to detect proteins interrupting PPI.  In this system, the bait is fused to an 
intact receptor and the prey is fused to an inhibitor of the signalling such as a phosphatase.  If bait 
and prey interact, the reporter gene is silent, but if a molecule interrupts this interaction, the reporter 
gene is induced (Lievens et al. 2012).
(iv) Resonance energy transfer systems.  Another particular class of mammalian two-hybrids are 
the Fluorescence Resonance Energy Transfer (FRET) and the Bioluminescence Resonance Energy 
Transfer (BRET) systems.  FRET and BRET are based on the same principle.  Proteins are fused to 
small molecules between which energy transfer occurs only if the proteins of interest are in close 
proximity.  One molecule, termed the «donor», transfers energy to a second molecule termed the 
«acceptor», which in turn emits fluorescence.  The PPI is thus measured at the emission wavelength 
of the acceptor molecule (Figure 13). In FRET, the partners tested are both fused to fluorescent 
proteins with overlapping emission and excitation spectra. In BRET, the donor molecule is a 
luciferase protein and the acceptor is a fluorescent protein (often YFP). These techniques allow real-
time visualisation of interactions.  The use of BRET compared to FRET has the advantage to avoid 
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photobleaching problems and thus to follow interaction for longer time-lapse.  However, subcellular 
resolution is better with FRET.  Those techniques are very powerful but also heavy to set up and 
require technical expertise (Boute et al. 2002, Piston and Kremers 2007, Lievens et al. 2009).  
Figure 12. Mammalian protein-protein interaction trap (MAPPIT). 
Bait (B) is fused to the cytosolic portion of a mutated receptor unable to induce JAK/STAT signalling pathway. Prey (P) 
is fused to an intact cytosolic portion of a receptor. Bait prey interaction allows STAT recruitment by the receptor and 
phosphorylation by the JAKs. Once phosphorylated,  STATs dimerize and translocate in the nucleus where they bind to 
STAT binding elements and induces reporter gene transcription.
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Figure 13.  Fluorescence/bioluminescence resonance energy transfer systems (FRET-BRET).
FRET and BRET are based on the same principle of energy transfer between a donor and an acceptor molecule. In 
FRET, bait (B) and prey (P) are fused to fluorescent molecules.  In BRET, bait and prey are fused to a luciferase and a 
fluorescent molecule respectively.  If bait and prey interact, the donor molecule that is excited transfers its energy to the 
acceptor molecule, which in turn emits at his own wavelength.   FRET and BRET are reported when a signal is detected 
at the acceptor molecule wavelength.  
4.1.3 Proximity Ligation Assay
Proximity ligation assay (PLA) was developed by Söderberg and colleagues and allow to detect PPI 
of endogenous proteins in cells or tissue sections (Soderberg et al. 2008). The PLA technique works 
as follows: each of the two proteins to assay for interaction are detected with a specific primary 
antibody.  The two primary antibodies must be derived from different species (e.g. mouse and 
rabbit) or from different isotypes (e.g. mouse IgG1 and mouse IgG2a). In a second step, secondary 
antibodies, conjugated to oligonucleotides, recognise the primary antibodies according to their 
species isotype. Two «connector oligonucleotides» are used to ligate the antibody  oligonucleotides 
but this requires proximity between the two secondary antibodies, and thus interaction of the 
assayed proteins.  If the proteins indeed interact, a proper DNA ligation product is formed and can 
serve as a template for rolling-circle amplification. This generates a long single-stranded DNA 
molecule that can be detected by fluorescent probes (Figure 14). 
PLA has the advantage to reveal an interaction between endogenous proteins (not fusion proteins 
resulting from transfection). PLA can be performed on cells in suspension and then detected by 
FACS, but it is most frequently  achieved on cells and tissue sections and detected by fluorescence 
microscopy (in-situ PLA). When detecting PLA signals by fluorescence microscopy, each pair of 
interacting protein is represented by an individual fluorescent dot that  can be localised in the cell. 
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When detecting PLA signals by FACS, the information about the localisation of the interaction is 
lost but allows a more quantitative evaluation of the interactions.  The obvious limitation of the 
PLA technique is the availability of antibodies targeting the assayed proteins and the possibility  to 
use these antibodies in combination. 
In-situ PLA was applied to the study  of the kinetics of SMAD2/SMAD4 and SMAD3/SMAD4 
complex translocation in the nucleus after TGF-β treatment (Zieba et al. 2012). Sundqvist and co-
workers used PLA to highlight the interaction of AP-1 family  transcription factors with the SMADs. 
This technique is suited for surface proteins as well as cytosolic and nuclear proteins.  
Figure 14.  Proximity ligation assay (PLA).  
Bait (B) and prey (P) are recognised by specific antibodies derived from different animal species. Those primary 
antibodies are then recognised by species secondary antibodies conjugated to oligonucleotides.  If bait and prey interact, 
oligonucleotides bound to the antibodies are close enough to be linked through connector oligonucleotides which are 
then ligated.  The so-formed template is amplified by rolling circle amplification. DNA is then detected by fluorescent 
probes.  
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4.2 PPI detection by biochemical methods
Simultaneous to the development of yeast and mammalian two-hybrid systems, several biochemical 
techniques were developed to assess PPI.  
4.2.1. Co-immunoprecipitation and co-Affinity Purification
Co-ImmunoPrecipitation (co-IP) and co-Affinity Purification (co-AP) are frequently used to test 
interactions and are based on the same principle (Monti et al. 2005). In co-IP, a target protein is 
purified from a whole cell extract using a specific antibody (Figure 15a).  The proteins interacting 
with the target remain attached to the latter. Complexes of antibody-target-interacting protein are 
fixed on a solid surface (beads or columns) through binding of the antibody. Several washing steps 
are applied to remove proteins attached non-specifically. Molecules remaining after washing are 
eluted using denaturing agents (SDS), extreme pH or high salt concentrations. The eluted proteins 
are then either analysed either by Western Blot (WB), if one searches for a particular interacting 
protein, or identified by techniques like Mass Spectrometry (Phizicky and Fields 1995).  
Co-IP between endogenous proteins is a highly reliable technique to confirm an interaction between 
two partners.  However, successful co-IP with endogenous interacting proteins are not so easy to 
obtain.  First, this method is not convenient for labile interactions since it is not sensitive and weak 
interactants are generally lost during the washing steps.  To increase the sensitivity of co-IP, cross-
linking of proteins, which implies the chemically-mediated establishment of covalent bounds 
between closely interacting proteins, may be used to favour the detection of weak interactions. 
However this may lead to the detection of false positive interactions.  Second, the availability of 
antibodies able to purify  the native target proteins without disrupting its interactions is often a 
limiting step.  
Co-AP is similar to co-IP and can serve as alternative when no antibody  targeting the protein of 
interest is available. Here, isolation of the target protein is performed via a «tag» linked to the target 
protein (Figure 15b). The tags are chosen based on their ability to bind with high affinity  to 
molecules that  can serve for the purification step.  Many  different tags that have been designed, and 
classically include Glutathione-S-Transferase (GST-tag), Strep-tag, Calmodulin Binding Protein 
(CBP), or epitopes recognised by monoclonal antibodies (Monti et al. 2005).  When expressed in 
cells, the tagged target protein binds to its partner(s). After cell lysis, the target is purified by 
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binding to molecule that has a high affinity  for the tag (for the examples cited above, this would 
correspond to glutathione, biotin, calmodulin or a specific monoclonal antibody, respectively) .  
Since co-IP and co-AP both involve cell lysis, these systems give no information about the 
localisation of the PPI in the cell.  Subcellular fractionation can be performed before target isolation 
to give an indication of its location. To isolate partners of surface proteins, another strategy  is to 
incubate whole cells in the presence of the antibody recognising a surface target. The antibody is 
first allowed to bind to its antigen, and cells are lysed in a second step. Antibodies are then 
immobilised on a solid surface as for a classical IP.  This way, only surface interactants are isolated.
The challenges of co-IP and co-AP methods are mostly related to the high proportion of 
contaminants that are not specifically bound to the target. To address this issue, the group of 
Seraphin developed the so-called Tandem Affinity Purification or TAP method (Puig et al. 2001, Xu 
et al. 2010).  Two epitope tags separated by a TEV cleavage site are fused to a target  bait.  This 
allows to purify  the bait with the associated preys on the basis of a first tag.  Upon cleavage by 
TEV protease, the second tag is revealed and used for a subsequent purification step. TAP methods 
allow purification of large protein complexes and leads to lower background compared to the co-
AP technique.  Classically, the two epitope tags used are protein A and CBP (Figure 16).  TAP has 
been successfully applied in many prokaryotic and eukaryotic cell lines (Xu et al. 2010).
When looking for new interacting partners of a target protein, different strategies may be used. 
Proteins co-purified or co-immunoprecipitated with the protein of interest are often identified by 
Mass Spectrometry  (MS). These techniques are then termed IP-MS or AP-MS.  This usually leads 
to the identification of numerous potential interactants, and confirmation with other techniques is 
needed to exclude false positives.  
Compared to two-hybrid techniques, the interaction detected by  IP- or AP-MS does not require to 
be a direct  interaction. Indeed, if the interaction between multiple partners is strong enough, and 
resists to all steps of the procedure, different members of the complex may be identified at once. 
 
A very  interesting study comparing data collected from AP-MS and Y2H screenings was performed 
by the group of Vidal in 2008 (Yu et al. 2008).  Comparing the data from several publications, they 
concluded that AP-MS and Y2H screenings lead to data that are equal in quality, but the identified 
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interactions are different in nature.  Their computational analysis led to the conclusion that AP-MS 
mostly  reveals interactions between large and stable complexes from a same pathway, while Y2H 
identifies mostly binary interactions enriched in transient and «condition-specific» interactions. 
This suggest that Y2H screens allow to link several pathways or identify transient TF associations 
for example, which would fail to be identified with AP-MS methods.  Overall, this study confirmed 
that both approaches are complementary and a combination is needed to complete the 
understanding of a complex PPI network. 
 
Figure 15. Co-Immunoprecipitation (co-IP) (a) and co-Affinity Purification (co-AP) (b). 
Protein complexes (endogenous proteins for co-IP and fusion protein for co-AP) are isolated from cell extracts using 
target specific antibody coated beads (a) or affinity Tag column purification (b).  Upon removal of non-specific binders, 
protein target and partners are eluted and loaded on SDS-PAGE gel.  Proteins co-IPd or co-APd can be identified by 
Western Blot or screened by MS.
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Figure 16.  Tandem Affinity Purification (TAP).  
The tandem affinity purification (TAP) tag consists of three components: a calmodulin-binding peptide (CBP), a 
tobacco etch virus (TEV) protease cleavage site and Protein A as an immunoglobulin G (IgG)-binding domain. Cells are 
transfected to produce TAP-tagged protein(s). Extracts are then prepared under mild conditions and TAP is carried out 
to conserve protein complexes integrity. The first column consists of IgG coated beads. TEV protease cleaves the 
immobilized multiprotein complexes. Another round of binding is carried out on a second column that consists of 
calmodulin coated beads. The complex is then eluted and the proteins co-purified are analysed by MS.
4.2.2. Luminescence-based mammalian interactome mapping  
The luminescence-based mammalian interactome mapping or «LUMIER» is a technique combining 
two-hybrid and co-IP techniques that is developed to assay  dynamic PPI in a high-throughput 
setting (Barrios-Rodiles et al. 2005). In LUMIER, two hybrid proteins are coexpressed in 
mammalian cells: one contains a Flag tag to enable IP and the other is fused to a Renilla Luciferase 
(RL) reporter.  Interaction between the two partners is determined by detecting  luciferase activity 
on immunoprecipitates using an antibody against the Flag tag (Figure 17).  This assay was 
performed in a large scale analysis by the group of J. Wrana in the TGF-β signalling pathway, 
which relies mostly on dynamic PPI occurring upon residue phosphorylation.  They coexpressed in 
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293T cells RL fused to known members of the TGF-β pathway  and 518 flag-tagged preys.  Cells 
were treated or not with TGF-β.  Because of the huge amount of data provided by this assay, 
authors automated the detection of RL activity  for each Flag precipitate. Their results highlighted 
links between the TGF-β pathway  to other networks including the p21-activated kinase and 
Occludin (Barrios-Rodiles et al. 2005). This system reveals dynamic, novel or validated, 
interactions induced by extracellular signals.  
Figure 17. Luminescence-based Mammalian interactome mapping (LUMIER).
Renilla Luciferase-tagged bait is coexpressed in mammalian cells with Flag-tagged preys.  Interaction between bait and 
prey is determined by luciferase activity in anti-Flag immunoprecipitates.
4.2.3. Overlay or Far Western
A technique called Far Western Blotting (or Far Overlay) is a method derived from classical WB to 
identify PPI.  Prey proteins from a cell lysate are separated by PolyAcrylamide Gel Electrophoresis 
(PAGE) and then transferred on a membrane and probed («overlaid») with a bait  (Figure 18).  The 
bait bound to its prey(s) is detected with a specific antibody and revealed as an usual WB 
(Edmondson and Dent 2001).  In this assay, the bait-prey interaction must be a direct interaction to 
be detected.  To ensure proper detection of bait/prey  interaction, the preys should be in their native 
conformation.  Therefore, prey proteins can be separated in native gels or renatured after transfer on 
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the membrane.  Moreover, to facilitate bait detection and avoid antibody requirement, baits may be 
fused to tags or linked to biotin or radioactive labels. Preys detected by Far Western then used to be 
identified by MS.
Figure 18.  Far Western of (Far Overlay). 
Prey proteins are first separated by PAGE and then transferred on membrane (PVDF or nitrocellulose). Membranes are 
«overlaid»  with bait protein which is allowed to bind to its prey(s). Upon washing of the membrane,  the bait that 
remains bound to the membrane is detected with a specific antibody like in classical WB. Prey proteins may be 
identified by their size, and sequenced by MS.  
4.2.4. Phage Display
The phage display  technique was first described in 1985 by G. Smith as a technique to identify and 
clone a gene for which an antibody is available (Smith 1985).  The screening system uses phages 
(frequently bacteriophage M13) «displaying» at their surface prey  proteins through a fusion with  a 
phage coat protein (frequently pIII coat protein). Viruses presenting proteins at  their surface are 
bound to bait  proteins immobilised on a solid support. Upon washings only  viruses that display 
preys interacting with the bait remain attached to the solid support.  Bound phages are eluted and 
amplified in E. coli. They are then used for repeated cycles of selection  and amplification, which 
are necessary  to amplify specifically  bound phages over non-specific binders (Sundell and Ivarsson 
2014).  The cDNA coding for the isolated preys is then identified by sequencing (Figure 19).  As for 
Y2H and Far Western, this technique allows identification of direct interactions between two 
proteins and is not  suited for large protein complexes. However, it is a powerful screening approach 
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that has been used for the identification of PPI, and widely applied for antibody  screenings (Chan et 
al. 2014, Sundell and Ivarsson 2014). Recently, our group derived mAbs targeting GARP using 
phage cDNA libraries encoding immunoglobulin Fab fragments as preys, and GARP/TGF-β 
complexes as baits.  This technique allowed to derive a mAb recognising the GARP/TGF-β 
complex and inhibiting Treg function in vitro and in vivo (Cuende et al. manuscript submitted).
Figure 19. Phage display technique.  
Adapted from Sundell and Ivarsson 2014.  
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4.3  The Interactome
Two-hybrid screenings as well as biochemical methods have generated over the past decades an 
endless amount of data concerning PPI in many different organisms.  The ongoing challenging work 
of researchers is to design interaction networks called «interactomes» which are a representation of 
each binary interaction occurring in a given organism, cell type or pathway. Interactome approaches 
aim to provide an understanding of the complex protein interplays and help to predict  the effects of 
drug therapies (Lievens et al. 2009).  
Each member of an interaction network is characterised by its degree of connectivity.  Nodes that 
are highly  connected to other proteins are called «hubs».  Yu et al. observed a striking difference in 
the interactomes provided by  AP-MS and Y2H (Yu et al. 2008).  The AP-MS reveals interactomes 
with a majority of «party-hubs» which are considered static interacting partners of a specific 
biological process.  In contrast, Y2H methods reveals a majority of «date-hubs» which corresponds 
to dynamically interacting proteins.  A representation of these interactomes are shown in Figure 20 .  
                   
                        
            
Figure 20. Adapted from Yu et al. 2008.  
Network analysis of Y2H (left) and AP/MS (right) datasets.
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Aim of the study
Production of active TGF-β1 is one important mechanism used by human Tregs to suppress other 
immune cells.  The steps leading to this production are not yet fully  elucidated.  We know that TCR 
stimulation induces latent TGF-β1 presentation on the surface of Tregs, and this occurs through 
binding to GARP. Blocking anti-GARP antibodies inhibit active TGF-β1 production by  TCR- 
stimulated Tregs, demonstrating that GARP is required for TGF-β1 activation in these cells. 
However, Th lymphocytes transduced with GARP present latent TGF-β1 at their surface but are 
unable to produce the active cytokine.  Thus, although GARP is required for TGF-β1 activation by 
Tregs, it is not sufficient. We hypothesised that additional proteins present in Tregs but not in Th 
cells associate with GARP/TGF-β1 complexes and contribute to TGF-β1 activation.  
The objectives of this work were to identify new protein partners of GARP that are expressed by 
stimulated Tregs, but not by Th cells, and that regulate TGF-β1 production in Tregs.   We used two 
approaches to identify new GARP partners:
(i) a yeast two-hybrid system known as «split-ubiquitin» or «Membrane Yeast  Two-
Hybrid» (MYTH), using GARP as a bait  to screen a prey cDNA library prepared from TCR- 
stimulated Tregs,  
(ii) an IP-MS approach, in which we immunoprecipitated GARP from stimulated Treg cell 
lysates and attempted to identify co-immunoprecipitated proteins by MS. 
Isolated protein candidates are then evaluated for their role in the regulation of TGF-β1 production 
by human Tregs.  
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Abstract
Production of active TGF-β1 is one mechanism by which human regulatory T cells (Tregs) suppress 
immune responses. This production is regulated by GARP, a transmembrane protein present on 
stimulated Tregs, but not on other T lymphocytes (Th and CTLs). GARP forms disulfide bonds with 
proTGF-β1, favors its cleavage into latent inactive TGF-β1, induces the secretion and surface 
presentation of GARP/latent TGF-β1 complexes, and is required for the activation of the cytokine. 
Forced expression of GARP in non-Treg cells, however, is not sufficient to induce TGF-β1 
activation, suggesting that additional Treg-specific protein(s) associated with GARP/TGF-β1 
complexes regulate TGF-β1 production in Tregs. We searched for such proteins by yeast two-
hybrid, using GARP as a bait  to screen a human Treg cDNA library. Here we identified LAPTM4B 
(Lysosomal-Associated Transmembrane Protein 4B), which interacts with GARP in mammalian 
cells and is expressed at higher levels in Tregs than in Th cells. LAPTM4B decreases cleavage of 
proTGF-β1, secretion of soluble latent TGF-β1 and surface presentation of GARP/TGF-β1 
complexes by Tregs, but does not contribute to TGF-β1 activation. Thus LAPTM4B binds to 
GARP and decreases TGF-β1 production in human Tregs. It may play a role in the control of 
immune responses by decreasing Treg immunosuppression. 
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Introduction
Regulatory T lymphocytes (Tregs) are a subset of CD4+ T cells that maintain immune tolerance by 
suppressing auto-reactive T cells (Sakaguchi et al. 2010, Josefowicz et al. 2012). Their 
development and function requires transcription factor FOXP3, as illustrated by the severe 
autoimmune syndrome that affects mice and humans carrying a mutated FOXP3 gene (Bennett  et 
al. 2001, Brunkow et al. 2001, Wildin et al. 2001). Foxp3 expression is a specific marker of Tregs 
in mice. This is not true in humans, where non-regulatory  CD4+ or CD8+ T lymphocytes transiently 
express FOXP3 upon T cell receptor stimulation (Sakaguchi et al. 2010). Stable FOXP3 expression, 
a hallmark of Tregs in mice and humans, is ensured by the demethylation of a conserved non-
coding region of gene FOXP3, called FOXP3i1, TSDR or CNS2 (Baron et al. 2007, Floess et al. 
2007, Polansky  et al. 2008, Stockis et al. 2009a, Zheng et al. 2010). Demethylated FOXP3i1 can 
serve to identify and quantify Tregs in human blood or cell samples (Wieczorek et al. 2009, de 
Vries et al. 2011, Gauthy et al. 2013). 
Depending on the context or the cell type to suppress, Tregs use various mechanisms of immune 
suppression. One mechanism implies the production of the potent immunosuppressive cytokine 
TGF-β1 (Vignali et al. 2008, Josefowicz  et al. 2012). Its production by Tregs is regulated by GARP, 
a surface protein expressed on stimulated Tregs but no other T lymphocytes (Wang et al. 2008, Tran 
et al. 2009, Stockis et al. 2009b, Gauthy et al. 2013). TGF-β1 is synthesized in all cell types as a 
homodimeric proTGF-β1 precursor (Figure 1) (ten Dijke and Arthur 2007, Travis and Sheppard 
2014). FURIN cleaves proTGF-β1 to generate a C-terminal fragment, or mature TGF-β1, which 
remains non-covalently  bound to the N-terminal fragment known as LAP (Latency-Associated 
Peptide). This complex, called latent TGF-β1, is inactive because LAP prevents mature TGF-β1 
from binding to its receptor. Latent TGF-β1 is secreted by most  cell types as a soluble form. In the 
secretory pathway of stimulated human Tregs, GARP forms disulfide bonds with the proTGF-β1 
precursor and favors its FURIN-dependent cleavage into latent  TGF-β1 (Wang et al. 2012, Gauthy 
et al. 2013). GARP/latent TGF-β1 complexes are then presented on the Treg surface (Tran et al. 
2009, Stockis et al. 2009b, Gauthy  et al. 2013). Stimulated Tregs release mature TGF-β1 from 
surface GARP/latent  TGF-β1 complexes, a process called “latent TGF-β1 activation”. Binding of 
active TGF-β1 to its receptor leads to autocrine and paracrine signaling followed by 
phosphorylation of SMAD transcription factors (Stockis et al. 2009a). We have recently produced 
GARP monoclonal antibodies that are able to block TGF-β1 activation by Tregs, thus GARP is 
necessary  for this activation (Cuende et al. manuscript submitted). But it  is not sufficient because 
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Th lymphocytes and 293T cells transfected with GARP present GARP/latent TGF-β1 complexes on 
their surface but do not produce active TGF-β1 (Stockis et al. 2009b). This suggests that at least 
one additional protein expressed in Tregs, but not in Th lymphocytes or 293T cells, cooperates with 
GARP to activate latent TGF-β1. 
Here, we sought to identify proteins that bind to GARP, are expressed at  higher levels in Tregs than 
in Th cells, and contribute to the regulation of TGF-β1 production by human Tregs. We identified 
Lysosomal-Associated Transmembrane 4B (LAPTM4B), and showed that LAPTM4B is a negative 
regulator of TGF-β1 production in human Tregs.
Figure 1. GARP and production of TGF-β1. 
Production and processing of TGF-β1 in cells expressing GARP (Tregs) or not (other cell types). Double curves 
represent cell membranes, with the secretory pathway as a circle. In latent TGF-β1, the Latency-Associated Peptide 
(LAP) is represented as thick black lines, and the mature TGF-β1 as green lines. Thin black lines represent disuflide 
bonds. Although not shown in this figure, in Tregs latent TGF-β1 can also be secreted as a soluble form in which it is 
covalently associated to GARP (Gauthy et al. 2013).
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Results
Identification of GARP binding proteins in a yeast two-hybrid system
To identify proteins binding to GARP in human Tregs, we used the yeast two-hybrid system known 
as “split-ubiquitin”. As shown in Figure 2A, the bait is a transmembrane protein fused to the C-
terminal moiety of Ubiquitin (CUB) and to the LexA-VP16 hybrid transcription factor.  Due to the 
fusion, LexA-VP16 is retained in the cytoplasm and cannot exert transcriptional activity. The prey 
cDNA library  encodes proteins fused to the N-terminal moiety of Ubiquitin (NUBG), which harbors 
a mutation that prevents spontaneous association with CUB.  In yeasts transfected with bait and 
prey, reconstitution of a functional Ubiquitin by reassembly of CUB and NUBG occurs only if bait 
and prey interact.  Reconstituted Ubiquitin is recognized by  Ubiquitin specific proteases (UBPs) 
that will cleave off LexA-VP16 from the bait, allowing its migration to the nucleus, transcription of 
HIS3 and ADE2 reporter genes and growth of yeast  on media lacking histidine and adenine (Figure 
2A).  It  must be noted that productive bait/prey interactions occur only  if CUB and NUBG are both 
located in the cytosol.  Thus, when NUBG is fused to the N-terminal extremity of preys, only 
cytosolic proteins or type II membrane proteins can be identified using this approach. Here, we used 
GARP-CUB-LexA-VP16 as a bait and a prey cDNA library constructed from 3 different human 
Treg clones stimulated during 24 hours with anti-CD3 and anti-CD28 antibodies (Stockis et al. 
2009a). 
We transformed the Treg cDNA library  in yeasts expressing GARP-CUB-LexA-VP16 (Figure 2B). 
Selection on HIS- ADE- medium yielded 2371 yeast clones in which the bait interacted with a prey. 
We sequenced prey cDNAs from 191 selected clones.  Of these, 101 encoded out of frame fusions 
or contained non-coding genomic DNA, whereas 90 encoded proteins fused in frame with the 
NUBG coding sequence. The list of these cDNAs was compared to that of cDNAs frequently 
isolated in unrelated split-ubiquitin screens (Dualsystems and our unpublished data) to exclude 45 
cDNAs, which were likely to be false positives. We further excluded 31 other cDNAs encoding 
proteins involved in protein translation or post-translational modifications, or proteins that do not 
have a predicted N-terminus in the cytosol. Altogether, this left us with 14 cDNAs encoding 
proteins that potentially interact with GARP.  
We examined the expression profiles of the corresponding mRNAs in stimulated human Treg and 
Th clones, using available expression microarray data (Figure 2C, (Stockis et al. 2009a)). Two 
mRNAs, LAPTM4B and CD9, were expressed at  >7-fold higher levels in Treg versus Th clones 
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(Figure 1C). As CD9 expression in Tregs was low and could not be confirmed to be higher than in 
Th by RT-qPCR, we focused our analyses on LAPTM4B.
Figure 2. Identification of potential GARP binding partners using a two-hybrid split-ubiquitin system in yeast. 
A. Schematic representation of the yeast two-hybrid «split-ubiquitin» system. 
B. Screening of a Treg cDNA library to identify GARP binding partners using the split-ubiquitin system in yeast. 
C. List of 14 potential GARP partners and their expression levels in TCR-stimulated human Treg and Th clones (means 
of 3 or 2 clones, respectively) as measured with Affymetrix expression microarrays (Stockis et al. 2009a).
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Two mRNA variants of LAPTM4B are expressed in Tregs 
According to public databases, transmembrane protein LAPTM4B is encoded by a gene reported to 
comprise 7 exons: E1a and E2 to E7. The mRNA variant isolated from our prey cDNA library 
contained an alternative first exon, which we named E1b (Figure 3).
To determine which LAPTM4B mRNA variants are expressed in human Tregs, we analyzed 
stimulated Treg clones by  RT-PCR. Sense primer “A1”, located immediately upstream of the 
described start codon in the RefSeq sequence, combined to antisense primer “R” did not yield a 
PCR amplification product, indicating that the RefSeq LAPTM4B mRNA is not expressed in human 
Tregs (Figure 3 and data not  shown). Primer “A2”, straddling a described alternative start  codon 
(Shao et al. 2003), and “R” amplified a product of 677 bp, indicating that  an mRNA variant that we 
will refer to as “Variant a” (Va) is expressed in human Tregs. The precise 5’ extremity  of Va is not 
known. Finally, primers “B” and “R” yielded a product of 608 bp, indicating that human Tregs 
express a second mRNA variant that we named “Variant b” (Vb).  We used 5’RACE to identify  the 
5’ extremity of Vb (Figure 3). 
LAPTM4B variants have multiple AUG start codons in frame with the longest open reading frame, 
and thus potentially encode several LAPTM4B isoforms, which differ only by the length of their N 
terminus (Figure 3). Two isoforms were previously described (Shao et al. 2003): LAPTM4Biso35 (35 
kDa) is encoded by the RefSeq variant only, whereas LAPTM4Biso24 (24 kDa) is encoded by 
RefSeq and Va variants. LAPTM4B Vb can encode a previously  unknown 20 kDa isoform, named 
LAPTM4Biso20, which lacks the first 66 amino-acids of LAPTM4Biso24. RefSeq and Va variants also 
encode LAPTM4Biso20. Because Tregs express Va and Vb but not the RefSeq variant, we 
hypothesized that LAPTM4Biso24 and LAPTM4Biso20, but not  LAPTM4Biso35, are present in Tregs. 
We could not verify this hypothesis due to the lack of appropriate antibodies.
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Figure 3. LAPTM4B mRNA variants expressed in human Tregs encode two protein isoforms that differ at their 
N-terminus. 
Schematic representations of LAPTM4B gene, mRNA variants and proteins isoforms. Exons are represented as boxes, 
introns as thin horizontal lines. All start and stop codons in frame with the reported start of the RefSeq mRNA are 
indicated by vertical lines and by *,  respectively. Primers used for RT-PCR are indicated by arrows. LAPTM4B protein 
isoforms are represented as thick grey lines, with transmembrane domains highlighted in black. Double curved lines 
represent the plasma membrane. Start codons for the translation of the various protein isoforms are indicated above the 
representation of the gene.
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Va and Vb mRNA variants of LAPTM4B are expressed at higher levels in Tregs than in Th 
cells
We used RT-qPCR to measure expression levels of LAPTM4B Va and Vb mRNAs in resting or 
stimulated Treg and Th clones, using primers illustrated in Figure 3.  As shown in Figure 4, Va is 
expressed at higher levels than Vb in both types of T cells. Expression of Va was significantly 
higher in Treg than in Th clones, both at rest and after stimulation (on average 1,9-fold higher at 
rest, and 2,7-fold higher after stimulation).  Expression of Vb was detected in stimulated Treg 
clones only (>3 copies/105 EF-1 copies in 5 out of 7 stimulated Treg clones).
Altogether, LAPTM4B Va and Vb variants are expressed at higher levels in stimulated human Tregs 
than in resting Tregs and in resting or stimulated Th cells.
Figure 4. LAPTM4B Va and Vb are expressed at higher levels in human Tregs by comparison to Th cells. 
Expression of the indicated LAPTM4B mRNA variants was measured by RT-qPCR in 7 Th clones (blue lines) and 7 
Treg clones (red lines), at rest or 24 hours after stimulation with anti-CD3 and anti-CD28 antibodies.  * pvalue < 0,05; 
*** pvalue < 0,001 by Mann-Withney analysis.
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Confirmation of the interaction between GARP and LAPTM4B in mammalian cells
To test if GARP and LAPTM4B interact in mammalian cells, we used a protein complementation 
assay in which two distinct, inactive fragments of humanized Gaussia Luciferase (hGLuc1 and 
hGLuc2) are fused to the C-terminus of candidate proteins and expressed in 293T cells (Remy and 
Michnick 2006). Luciferase activity  is recovered only if candidate proteins interact with each other. 
We co-transfected constructs encoding hGLuc1 fused to N-terminally HA-tagged GARP, and 
hGLuc2 fused to HA-tagged LAPTM4B.  Two LAPMT4B constructs were tested, encoding only 
LAPTM4Biso20, or both LAPTM4Biso20 and LAPTM4Biso24 (i.e. LAPTM4Biso20/24). In the latter 
construct, only LAPTM4Biso24 is tagged with HA. All HA-tagged proteins were expressed at similar 
levels as determined by Western Blot (Figure 5, top panel).  High luciferase activity was detected in 
cells co-expressing GARP and LAPTM4Biso24/20, or GARP and LAPTM4Biso20 (Figure 5, bottom 
panel).  As expected, no or very  low activity  was detected in cells expressing any protein alone, or 
in cells co-expressing GLuc fragments fused to GARP and EPOR, or to LAPTM4B and EPOR. 
EPOR was taken here as a negative control.
These results show that GARP and LAPTM4B isoforms interact in mammalian cells, and that the 
first 66 amino acids of LAPTM4Biso24 (Figure 2) are not required for this interaction.
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Figure 5. GARP interacts with LAPTM4B in mammalian cells.  
293T cells were transfected with constructs encoding GARP, LAPTM4B or negative control EPOR, fused to hGLuc1 or 
hGLuc2 as indicated.  The top panel shows Western Blot analysis of transfected cells. Bar graphs in the bottom panel 
show luciferase activity in live cells 24 hours after transfection. One experiment representative of three independent 
experiments is shown.
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Overexpression of LAPTM4B in 293T cells decreases cleavage of proTGF-β1, secretion of 
latent TGF-β1 and surface presentation of GARP-latent TGF-β1 complexes 
We used constructs encoding both LAPTM4Biso24 and LAPTM4Biso20 to evaluate whether 
LAPTM4B influences the regulation of TGF-β1 production by GARP in transfected 293T cells.
First, we examined by Western Blot whether LAPMT4B affects the cleavage of proTGF-β1 into 
latent TGF-β1 (Figure 6A). In cells transfected with TGFB1 alone (lane 2), proTGF-β1 is abundant 
but LAP or mature TGF-β1 (mTGF-β1) are not detected, indicating that cleavage of the precursor 
does not  occur at high levels. Co-transfection of TGFB1 with LAPTM4B (lane 3) does not increase 
cleavage. In contrast and as expected, co-transfection of TGFB1 with GARP (lane 6) induces 
cleavage as evidenced by the detection of abundant  LAP and mature TGF-β1. Co-transfection of 
LAPTM4B (lane 7) abolished this GARP-induced cleavage, an effect that was not observed upon 
co-transfection of CD9 (lane 8), taken here as a negative control.  As proTGF-β1 cleavage depends 
on FURIN, decreased proTGF-β1 cleavage in the presence of LAPTM4B could result from a direct 
effect on FURIN activity.  We examined whether the cleavage of endogenous proIGF1R, another 
known substrate of FURIN, into its β-subunit  was also reduced in 293T cells transfected with 
LAPTM4B, but this was not the case (Figure 6A). We also measured FURIN activity on an 
exogenous fluorogenic substrate, and the transfection of LAPTM4B did not decrease FURIN 
activity in this assay neither (Figure 6B). We conclude that LAPTM4B reduces the cleavage of 
proTGF-β1 in the presence of GARP, without reducing overall FURIN activity. 
We next examined whether this decreased cleavage of proTGF-β1 resulted in a reduction of latent 
TGF-β1 secretion. We indeed found 54% less latent TGF-β1 in the supernatants of 293T cells 
transfected with GARP, TGFB1 and LAPTM4B, by comparison to cells transfected with GARP and 
TGFB1 only  (Figure 6C). This effect was not observed with a negative control (CD9). Interestingly, 
the reduction of latent TGF-β1 secretion by  LAPTM4B was also observed in the absence of GARP, 
indicating that  the regulatory  effect of LAPTM4B on latent TGF-β1 secretion is not dependent on 
its interaction with GARP (Figure 6C). Incidentally and as expected, secretion of latent TGF-β1 
was lower in the presence of GARP because GARP tethers latent TGF-β1 at the 293T cell surface 
(Wang et al. 2012, Gauthy et al. 2013).
We then used flow cytometry  to examine whether LAPTM4B influenced surface levels of GARP or 
GARP/latent TGF-β1 complexes on transfected 293T cells. GARP levels were reduced by 45% 
upon co-transfection with LAPTM4B (Figure 6D). In cells transfected with GARP and TGFB1, co-
transfection of LAPMT4B reduced surface GARP by 67% and surface LAP by 73%. Surface levels 
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of unrelated proteins such as HLA-A2 or CD9 were not affected by co-expression of LAPTM4B. 
Thus, LAPTM4B reduces surface levels of GARP and GARP/latent TGF-β1 complexes. 
Finally, we tested whether LAPTM4B regulates latent TGF-β1 activation (Figure 6E). We used a 
reporter assay in which the luciferase gene is under the control of a CAGA promoter activated by 
SMAD2/3 transcription factors in response to TGF-β1 signals (Dennler et al. 1998). We transiently 
co-transfected the CAGA-LUC reporter with LAPTM4B in clones of 293T cells stably  expressing or 
not GARP and TGFB1. Co-transfection of LAPTM4B did not increase luciferase activity above 
background (i.e. transfection of reporter alone), indicating that LAPTM4B expression does not 
activate latent TGF-β1. This was true also in a clone stably expressing GARP, which is not 
sufficient to induce active TGF-β1 production (Figure 6E). As expected, high luciferase activity was 
induced by  transfection of integrin β6, or by addition of recombinant active TGF-β1, both taken 
here as a positive controls.We conclude that in transfected 293T cells LAPTM4B decreases the 
cleavage of proTGF-β1, the secretion of latent TGF-β1 and the surface presentation of GARP/latent 
TGF-β1 complexes, but does not activate latent TGF-β1 in cooperation with GARP. Thus 
LAPTM4B appears to be a negative regulator of TGF-β1 production in these cells.
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Figure 6.  LAPTM4B decreases cleavage of proTGF-β1, surface presentation of GARP/TGF-β1 complexes,  and 
secretion of latent TGF-β1. 
A. Cell lysates of transfected 293T cells were analysed by Western Blot. 
B.  Specific FURIN activity was measured in cell lysates 24 hours after transfection, by capturing FURIN on 
immobilized anti-FURIN antibody, then incubating captured proteins with the fluorogenic substrate pERTKR-AMC. 
Graphs show mean fluorescence intensity (MFI) at the indicated time after addition of the substrate.  The FURIN 
inhibitor Dec-RVKR-CMK was added to some conditions to verify the specificity of the assay.  
C. Concentration of latent TGF-β1 in the acid-treated supernatants was measured by ELISA. 
D. Surface levels of GARP, LAP, CD9 and HLA-A2 in transiently transfected 293T were assessed by FACS.
E.  Clones of 293T cells stably expressing or not human GARP and human TGF-β1 were transfected with LAPTM4B or 
ITGB6 together with CAGA-LUC reporter. Luciferase activity was measured 24 hours after transfection. Recombinant 
human (rh) TGF-β1 was added during 6 hours at 4 ng/mL in the positive control condition, as indicated. 
For A, C, D and E, 293T cells were transfected with TGFB1 construct coding for the full length pre-proTGF-β1 that is 
processed in 293T like in other cell types. 
LAPTM4B silencing in human polyclonal Tregs increases surface presentation of GARP/
TGF-β1 complexes and secretion of latent TGF-β1 
We next wished to evaluate whether LAPTM4B plays a role in human Tregs. Polyclonal Tregs were 
obtained by  a short in vitro amplification of blood CD4+CD25+CD127lo cells. They contained 47 % 
of cells with demethylated FOXP3i1. They were transfected with siRNAs and stimulated or not 
through their TCR to induce TGF-β1 activation. siLAPMT4B reduced the expression of LAPTM4B 
Va and Vb by ≥85% (Figure 7A). It increased by 41-53% the secretion of latent TGF-β1 by resting 
and stimulated Tregs (Figure 7C), and by >75% the surface presentation of GARP and latent TGF-
β1 on stimulated Tregs (Figure 7D). As expected, siLAPMT4B did not reduce the activation of TGF-
β1 by stimulated Tregs (Figure 7B). 
These results confirm that LAPTM4B is a negative regulator of TGF-β1 production in human 
Tregs.
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Figure 7. LAPTM4B decreases GARP surface levels and TGF-β secretion in polyclonal Tregs.  
Polyclonal human Tregs were transfected with the indicated siRNAs, left resting or stimulated with anti-CD3/CD28 
coated beads, and collected 78 hours after transfection. One experiment representative of three independent experiments 
is shown.  
A. RT-qPCR analysis of LAPTM4B Va and Vb expression.  
B. Western Blot analysis of cell lysates with anti-pSMAD2, anti-total SMAD2 and anti-β-ACTIN antibodies. Detection 
of pSMAD2 indicates active TGF-β production. 
C. ELISA on acid-treated supernatants to measure total TGF-β secretion. As no active TGF-β is detected in this assay, 
total TGF-β corresponds to latent TGF-β. 
D. Surface staining of GARP and LAP on stimulated cells was assessed by FACS using anti-GARP and anti-LAP 
antibodies respectively.
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Discussion
LAPTM4B belongs to a family of 3 glycoproteins with several transmembrane domains. The two 
other members of the family are LAPTM4A and LAPTM5, with 46% and 23% sequence identities 
with LAPTM4B, respectively. Little is known about the physiological function of LAPTM4B. In 
tumors, it appears to play an oncogenic role: high LAPTM4B levels are associated to poor 
prognosis in many types of cancers (Zhou et al. 2007, Yang et al. 2008, Zhou et al. 2008, Yang et 
al. 2010, Yang et al. 2010, Yin et al. 2011, Kang et al. 2012, Zhang et al. 2012, Tang et al. 2014, 
Zhang et al. 2014), and in vitro and in vivo analyses of cells in which LAPTM4B was overexpressed 
or silenced indicate that LAPTM4B favours proliferation, migration, invasion, tumorigenesis and 
metastasis (Liu et al. 2009, Yang et al. 2010). LAPTM4B may also contribute to chemotherapy 
resistance in breast cancer (Li et al. 2010).
Our results are the first to describe a function for LAPTM4B in the immune system: the decrease of 
latent TGF-β1 production, secretion and surface presentation in Tregs. Downregulation of surface 
presentation appears to result from a direct effect of LAPTM4B on surface GARP levels, as we 
show that  LAPTM4B interacts with GARP, a receptor for latent TGF-β1, and reduces surface 
GARP levels in transfected 293T cells in the absence of TGF-β1. Another LAPTM family member 
was reported to interact and to downregulate surface receptors on immune cells. Murine Laptm5 
binds to proteins of the T and B cell antigenic receptor complexes (TCR and BCR, respectively), 
and surface levels of TCR and BCR were higher on activated Laptm5-/- lymphocytes than in 
activated wild-type lymphocytes (Ouchida et al. 2008, Ouchida et al. 2010). C-terminal 
polyproline-tyrosine (PY) motifs target Laptm5 to lysosomes and are required for the Laptm5-
mediated downmodulation of surface TCR levels, suggesting a mechanism by  which Laptm5 
promotes lysosomal targeting and degradation of receptors to which it is bound (Pak et al. 2006, 
Ouchida et al. 2008). PY motifs are also present in the C-terminus of LAPTM4B (Ouchida et al. 
2008, Milkereit  and Rotin 2011). It is therefore possible that LAPTM4B downregulates GARP 
surface levels in human Tregs through a similar mechanism. However, we observed in transfected 
cells that GARP and LAPTM4B co-localize mostly  in the median Golgi, and that the localization of 
GARP was not modified in the presence of LAPTM4B (unpublished data). It is worth noting that 
the downregulation of latent TGF-β1 secretion by  LAPTM4B may occur through another 
mechanism, independent from GARP, as it was also observed in transfected 293T cells in the 
absence of GARP.
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Two isoforms of LAPTM4B, LAPTM4Biso35 and LAPTM4Biso24, were described previously  (Shao 
et al. 2003). Here we identify  in stimulated human Tregs an mRNA variant coding for a third, 
shorter isoform LAPTM4Biso20. Tregs also contain LAPTM4Biso24, but not LAPTM4Biso35. We 
showed that LAPTM4Biso20 interacts with GARP, indicating that the 66 N-terminal amino-acids of 
LAPTM4Biso24 are not required for the interaction. We could not determine whether LAPTM4Biso24 
also interacts with GARP, as all our constructs encoding LAPTM4Biso24 encode also 
LAPTM4Biso20. We do not know whether LAPTM4Biso24 or LAPTM4Biso20, or both regulate GARP 
and TGF-β1 production in Tregs, because our siRNA approach silenced all these LAPTM4B mRNA 
variants.
We report that LAPTM4B expression is higher in human Tregs than in Th cells. Overexpression of 
LAPTM4B in human or mouse Tregs, as well as in non-Treg cells transduced with FOXP3, was 
observed in published expression microarray data sets (Herman et al. 2004, Ocklenburg et al. 2006, 
Williams and Rudensky 2007), suggesting that gene LAPTM4B might be transcriptionally  regulated 
by FOXP3.
In conclusion, we uncovered an inhibitory  mechanism of GARP and TGF-β1 production mediated 
by LAPTM4B in human Tregs. Mechanisms of immunosuppression by human Tregs include the 
production of active TGF-β1, released from GARP/latent TGF-β1 complexes at the Treg surface 
(Tran et al. 2009, Stockis et al. 2009b). Tregs are potent inhibitors of immune responses, and 
excessive or insufficient Treg function is implicated in various human diseases. Pharmacological 
inhibition of LAPTM4B could increase TGF-β1 production, and hence Treg function, in patients 
suffering from autoimmune disease or undergoing allograft rejection.
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Materials and Methods
Ethics statement
Experiments with human cells were approved by our Institution’s ethics committee (Commission 
d'Ethique Biomédicale Hospitalo-Facultaire de l’Université catholique de Louvain), under 
registration number B403201110966. Written informed consent for the use of blood samples was 
not always obtained, in accordance with the Belgian law of 19 December 2008 which states that, in 
the absence of written opposition by the patient, consent is considered given for residual body 
material. This applies to blood samples from hemochromatosis patients. No patient opposed the use 
of blood samples. Data obtained from blood samples were analyzed anonymously.
Split-ubiquitin system in yeast
We used the split-ubiquitin system from Dualsystems Biotech AG, according to the manufacturer’s 
instructions. Briefly, GARP ORF was cloned into Sfi I sites of bait plasmid pBT3-SUC. The 
resulting plasmid was used to transform and select  GARP expressing NMY51 yeasts. A prey cDNA 
library was synthesized in pPR3N plasmid, starting from 2 µg of total RNA isolated from 3 
different human Treg clones stimulated during 24 hours with anti-CD3 and anti-CD28, as described 
(Stockis et al. 2009a). The Treg cDNA library contained 5,2x106 independent bacterial colonies, 
which were collected and used to purify plasmid DNA with the PureLink Plasmid Maxiprep kit 
(Life Technologies). Library plasmid DNA (28 µg) was transformed in GARP-expressing yeasts. 
An aliquot of transformed yeasts were selected on SD Leu-Trp- medium to assess transformation 
efficiency. The remaining yeasts were selected on SD Leu-Trp-His-Ade- to isolate clones 
transformed with potential GARP interactants.
RT-PCR and RT-qPCR analyses of LAPTM4B expression in human Tregs 
Total RNA was extracted, reverse transcribed and submitted to PCR or qPCR as previously 
described (Stockis et al. 2009a).  qPCR amplifications were done with ABI Prism 7300 Real Time 
PCR System (Applied Biosystems) under standard conditions: 95°C for 10 min, 45 cycles of 95°C 
for 15 s, and 60°C for 1 min.
Primer sequences (5’ to 3’):
A1: ATTAACAAGGATCCGCGATGACGTCACGGACTCGG 
A2: ATTAACAAGGATCCGCGATGAAGATGGTCGCGCCC
B: GCTCTATGGTGCCTGGGCCA
R: AACTGATTCTCGAGCGCAGACACGTAAGGTGGCGG
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qPCR for LAPTM4B Va : 
Sens: ACCATCCTGCTCGGCGTCTG ;
Anti-sens : CGGATCAGCCAGGGCACTCAAT 
qPCR for LAPTM4B Vb : 
Sens: GCTCTATGGTGCCTGGGCCA ; 
Anti-sens: CGGATCAGCCAGGGCACTCAAT ; 
FAM-TAMRA probe : GTACCACAGCATTGATGATCTCATTCCCC
T cell electroporation
Human polyclonal cell population enriched in Tregs (CD4+CD25+CD127lo cells) were isolated from 
hemochromatosis donors as previously described (Gauthy et al. 2013). Expanded Tregs (107 cells) 
were electroporated using the “Unstimulated Human T Cells 4D-Nucleofector solution” , mixed 
with siRNAs (5 µM of control siRNA #4390843 or siLAPTM4B #4392420 from Ambion) and 
electroporated in a 4D-Nucleofector instrument (Lonza). Immediately after transfection, cells were 
re-stimulated with anti-CD3/CD28 coated beads (Dynabeads Human T-Activator CD3/CD28, Life 
Technologies) in IMDM supplemented with 10% human serum, L-arginine, L-asparagine, L-
glutamine, β-mercaptoethanol (5x10-5M), methyl-tryptophane (200 µM). Analyses were performed 
78 hours after transfection.
Cell transfections
293T cells or a 293T cell clone stably expressing human GARP and human TGF-β1 were 
transiently  transfected with plasmids indicated in the figures using the TransIT-LT1 transfection 
Reagent (Mirus Bio). Cells were analysed 24 hours after transfection. Luciferase activity was 
measured with the Britelite Plus Reporter Gene Assay System (Perkin Elmer).
Western Blot 
Cells were lysed in Laemmli buffer supplemented with 5% β-mercaptoethanol as previously 
described (Stockis et al. 2009a) and submitted to SDS-PAGE and Western Blot with the following 
primary antibodies, as indicated in the figures: anti-GARP (Enzo Life Sciences #ALX-804-867), 
anti-TGF-β1 (BD Pharmingen #555052), biotinylated anti-LAP (R&D Systems #BAF246), anti-
Myc (ROCHE # 11-667-149-001), anti-PSMAD2 (Cell Signaling #3108), anti-SMAD2 (Cell 
Signaling #3122), anti-IGF1Rβ (Cell Signaling #3027), anti-HA (Eurogentec #MMS-101R) or anti-
β-ACTIN (Sigma #A5441).
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FACS analysis
Cells were stained with mouse monoclonal biotinylated anti-GARP antibody (clone MHGARP6, 
manuscript submitted) followed by streptavidin coupled to PE (BD Pharmingen #554061), anti-
LAP antibody coupled to APC (R&D Systems #27232), anti-CD9 antibody coupled to PE 
(BioLegend #312105), anti-HLA-A2 antibody coupled to FITC (BioLegend #343304).  Data were 
collected on a FACS LSR Fortessa (BD Biosciences) and analyzed with the FlowJo software (Tree 
Star). 
Latent TGF-β1 concentrations in supernatants
Acidified supernatants were analyzed by ELISA according to the manufacturer’s instructions 
(Human TGF-β1 duoset, R&D Systems).
Fluorogenic assay for FURIN-specific activity
Assays were performed as described by  Bourne et al. (Bourne and Grainger 2011). Briefly, 
transfected 293T cells were lysed in 5x lysis buffer (500 mM  HEPES pH 7.0, 2,5% Triton X-100, 5 
mM calcium chloride, 5 mM ß-mercaptoethanol). Lysates containing 3.3x105 cell equivalents were 
seeded in black opaque 96 well plates pre-coated with a goat  polyclonal anti-FURIN antibody 
(R&D Systems #AF1503). Where indicated, the FURIN Inhibitor I Dec-RVKR-CMK (Calbiochem) 
was added at a final concentration of 50 µM. The FURIN fluorogenic peptide substrate pERTKR-
AMC (R&D Systems) was added at a final concentration of 100 µM. Fluorescence intensities were 
measured in duplicate wells every  3 min after addition of substrate, on a Victor X2 plate reader 
(Perkin Elmer), with excitation at 380 nm and emission at 460 nm.
Gaussia Luciferase complementation assay
Protein complementation assays (PCAs) were performed as described by Remy and Micknick 
(Remy and Michnick 2006). Briefly, 293T cells were transfected with Lipofectamine 2000 
Transfection Reagent in triplicate wells (96-well plates) with 0,05 µg of each plasmid (Life 
Technologies). Medium was changed to DMEM  without phenol red (Life technologies) and native 
coelenterazine (Nano technologies #303) was added on live cells 24 hours after transfection. 
Luciferase activities were measured on live cells in a VICTOR X Light device (Perkin Elmer).  
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2. Identification of proteins interacting with GARP in human Tregs by 
immunoprecipitation followed by mass spectrometry
Caroline Huygens*, Olivier Dedobbeleer*, Didier Vertommen, Pierre G. Coulie and Sophie Lucas
* These authors contributed equally to the work.
Abstract
Human regulatory  T lymphocytes (Tregs) are a subset of T lymphocytes that inhibit immune 
responses by  producing the immunosuppressive cytokine TGF-β1. Production of active TGF-β1 is a 
highly  regulated process. In human Tregs it  is controlled by GARP, a surface protein that is not 
expressed on other T lymphocytes (Th cells or CTLs). GARP interacts with the latent inactive form 
of TGF-β1, and is required for activation of the cytokine close to the Treg surface. Lentiviral-
mediated expression of GARP in Th cells is not sufficient to induce TGF-β1 activation, and we thus 
hypothesized that additional Treg proteins interacting with GARP/TGF-β1 complexes are required 
for this activation. To identify such proteins, we analyzed proteins co-immunoprecipitated with 
GARP in human Tregs by tandem mass spectrometry. We identified proteins candidates encoded by 
34 different genes. Of these, 7 were found expressed at higher levels in Tregs than in Th cells by 
RT-qPCR. We are in the process of cloning the 7 candidates to test their ability to activate TGF-β1 
in a luciferase reporter assay. At the present time, 4 candidates were tested but none was found to 
activate TGF-β1 in this system.
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Introduction
Human regulatory T cells (Tregs) are a subset of CD4+ T lymphocytes with immunosuppressive 
functions. They prevent autoimmune pathology by inhibiting auto-reactive T cells, but they  also 
play  detrimental roles in cancer patients by inhibiting anti-tumor immune responses (Sakaguchi et 
al. 2010, Josefowicz et al. 2012). Pharmacological targeting of Treg-mediated immunosuppression 
could be beneficial in several human pathologies. Multiple mechanisms of Treg suppression have 
been described in mice, where Tregs can be unambiguously identified based on the expression of 
transcription factor Foxp3. Which mechanisms play a role in humans is more difficult to study, 
notably because FOXP3 is also expressed in activated non-regulatory T cells, precluding the use of 
this protein marker to identify Tregs in humans (Sakaguchi et al. 2010). Stable FOXP3 expression, 
in contrast, is a hallmark of Tregs in both humans and mice. It is ensured by  demethylation of a 
regulatory region in the FOXP3 gene called FOXP3i1, CNS2 or TSDR (Baron et al. 2007, Floess et 
al. 2007, Polansky et al. 2008, Stockis et al. 2009a, Zheng et al. 2010). 
Using clones of human Tregs characterized by a demethylated FOXP3i1, we showed that human 
Tregs, but not other types of T cells (Th cells or CTLs) produce the active form of TGF-β1, a 
cytokine with well-known immunosuppressive functions (Stockis et al. 2009a, Oh and Li 2013). We 
also showed that TGF-β1 production by  human Tregs mediates their immune suppressive function 
in vitro and in vivo (Cuende et al. manuscript submitted, Stockis et al. 2009a). Targeting TGF-β1 
production by human Tregs could therefore serve to modulate their function in patients with 
autoimmune disease or cancer.
Most cells produce the latent inactive form of TGF-β1, whereas production of the active cytokine is 
highly  regulated and restricted to a few cell types. In Tregs, active TGF-β1 production is regulated 
by GARP, a transmembrane protein that is not expressed by other types of T cells (Cuende et al. 
manuscript submitted, Tran et al. 2009, Stockis et al. 2009b). GARP covalently  binds the 
homodimeric TGF-β1 precursor called proTGF-β1, and favors its cleavage by  FURIN into an N-
terminal fragment called LAP (Latency Associated Peptide) and a C-terminal fragment 
corresponding to mature TGF-β1 (Wang et al. 2012, Gauthy et al. 2013). LAP and mature TGF-β1 
remain non-covalently associated in a so-called latent TGF-β1 complex, in which the mature 
cytokine is prevented from binding to its receptor by LAP. To exert activity, mature TGF-β1 must 
be released from LAP, a process referred to as “TGF-β activation” (Travis and Sheppard 2014). 
GARP presents latent TGF-β1 at the Treg surface. Using blocking anti-GARP antibodies, we 
recently  showed that GARP is also required for TGF-β1 activation by Tregs (Cuende et al. 
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manuscript submitted). However, lentiviral-mediated expression of GARP in Th cells is not 
sufficient to induce TGF-β activation (Stockis et al. 2009b). We hypothesized that additional Treg 
protein(s) interacting with GARP/latent TGF-β1 complexes cooperate with GARP to activate TGF-
β1. In a previous attempt to identify such proteins, we screened a Treg cDNA library  by yeast two-
hybrid with GARP as a bait. This lead to the identification of LAPTM4B, which turned out to be a 
negative regulator of TGF-β1 production in Tregs (Huygens at al., manuscript submitted). Here, we 
used an alternative approach, based on the immunoprecipitation (IP) of GARP from stimulated 
human Treg clones, followed by  the identification of co-immunoprecipitated proteins by  Mass 
Spectrometry  (MS). We report the identification of 7 candidates that are expressed at higher levels 
in Tregs than Th cells. We are currently testing which candidates cooperate with GARP to activate 
TGF-β1. Such proteins could represent new pharmacological targets to achieve inhibition of Treg 
function in patients suffering form cancer or chronic infections.
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Results
Identification of proteins interacting with GARP by IP-MS in stimulated human Tregs.
We used a monoclonal anti-GARP antibody that recognizes GARP/latent TGF-β1 complexes 
(Cuende et al. manuscript submitted) to immunoprecipitate (IP) proteins from TCR-stimulated 
human Tregs. We used two types of human Tregs: a Treg clone (i.e. a pure population of cells with 
demethylated FOXP3i1, (Stockis et al. 2009a)), and polyclonal Tregs obtained by a short 
amplification of CD4+CD25hiCD127lo cells isolated from the blood of patient I. The polyclonal Treg 
population contained 56% of cells with demethylated FOXP3i1. Treg and control Th cells (blood 
CD4+CD25-CD127hi cells) were stimulated during 24 hours with anti-CD3 and anti-CD28 
antibodies prior to IP. We performed 3 independent anti-GARP IPs on Treg lysates (test IPs A, B 
and C), and 3 negative-control IPs using an isotype control on Treg lysates or an anti-GARP 
antibody on polyclonal Th cells which do not express GARP (control IPs D, E and F). 
Immunoprecipitated proteins were separated by  SDS-PAGE under reducing conditions, and gels 
were revealed by silver staining (Figure 1A). No band visible in test IPs but not in control IPs could 
be identified. We thus submitted the total immunoprecipitated products to analysis by tandem mass 
spectrometry  (MS). For this, we cut  out 21 contiguous horizontal fragments in each of the 6 lanes of 
the polyacrylamide gels (Figure 1A), and submitted proteins contained in each fragment to in-gel 
trypsin digestion, then to tandem MS. The peptides identified by MS were matched to a human 
protein database. This lead to the identification of 2092 proteins in the 3 test IPs (Figure 1B). We 
discarded from this list proteins also found in the negative control IPs (1641 proteins), and proteins 
with a predicted molecular weight (MW) at least 3x lower than the average MW expected in the gel 
fragment in which the peptide was identified. This left us with a list  of 431 potential GARP 
partners. We choose to focus our analysis on proteins encoded by genes expressed at higher levels 
in Treg than in Th clones. We thus examined previously reported expression microarray  data 
obtained from Treg and Th clones (Stockis et al. 2009a). Expression data was not available for 133 
candidates, due to the absence of corresponding probes on the microarray  chips. Of the 298 
remaining candidates, 35 were encoded by genes with a detectable expression level in Tregs that 
was ≥ 1,5x higher than in Th clones. As expected, GARP was present among these 35 proteins. 
Altogether, this left us with a list of 34 candidate proteins (Figure 1B and Table 1).
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Figure 1. Identification of proteins interacting with GARP in Tregs by IP-MS
A. Treg clone B1 and polyclonal Tregs or Th cells from patients I were stimulated for 24 hours with anti-CD3 and anti-
CD28 antibodies.  Cell lysates were immunoprecipitated with the indicated antibodies. IP products were submitted to 
SDS-PAGE and proteins were revealed by silver-staining. Each lane was cut into 21 horizontal bands, as indicated, and 
proteins in each band were submitted to MS analysis.
B. Strategy to select candidates identified by MS.
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Expression of candidates in Tregs and Th cells by RT-qPCR analysis
We next measured expression levels of the candidates by RT-qPCR, to verify the microarray data 
and extend our analysis to additional human Treg and Th cell samples. Here, we tested both T cell 
clones and polyclonal populations. Polyclonal Treg and Th populations were derived from patient 
II, as described above. The polyclonal Treg population from patient II contained 68% of cells with 
demethylated FOXP3i1. Expression levels of the various candidates were measured in resting cells 
or 24 hours after stimulation of their TCR (Figure 2 and Table 1). The expression of 4 candidate 
genes could not be examined because no specific PCR products were amplified with the primers 
that we had selected. Among the 30 remaining candidates, 7 showed a ≥ 3x higher expression in the 
stimulated Treg clone than in the Th clone, or in stimulated Treg polyclonal cells than in autologous 
Th polyclonal cells (candidates highlighted by grey boxes in Figure 2 and Table 1). Expression 
levels of 3 housekeeping genes were also examined as controls, and did not show comparable 
increases in Treg cell samples.
Analysis of the ability of candidates to activate TGF-β1 in 293T cells
To test if any of the 7 candidates is able to activate TGF-β1 in the presence of GARP, we resorted to 
a luciferase reporter assay  in a 293T cell clone stably  expressing GARP and TGF-β1. In this assay, 
cells are transiently co-transfected with a plasmid encoding one candidate together with a plasmid 
containing the luciferase gene under the control of a CAGA promoter, which is activated by 
SMAD2/3 transcription factors in response to TGF-β1 signals (Dennler et al. 1998). So far, we 
succeeded in cloning and testing 4 candidates (LEPR, ITGAM, SNRK, and NLRP1), but none was 
able to induce luciferase activity above levels observed in cells transfected with the reporter alone, 
or co-transfected with PLD3 encoding vector, taken here as a negative control (Figure 3). As 
expected, co-transfection of integrin β6, a known activator of TGF-β1 in epithelial cells, or addition 
of rhTGF-β1 induced high luciferase activity (Munger et al. 1999).
Figure 2. Expression of genes encoding potential GARP partners in Treg and Th cells. 
RNA was isolated from the indicated Treg and Th cell populations at rest (NS: no stimulation), and 24 hours after 
stimulation with anti-CD3 and anti-CD28 antibodies (S: stimulated). Sets of primers specific for the indicated genes 
were used to amplify reverse-transcribed RNA in real-time qPCR. Graphs show expression levels relative to expression 
in the non-stimulated polyclonal Th II cells (2∆Ct method). Relative expression levels of GARP and of three 
housekeeping genes (EF1, βACTIN and β2-MICROGLOBULIN) are shown at the bottom for comparison.
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Figure 3. Luciferase reporter assay to measure TGF-β1 activation in a 293T cell clone stably expressing GARP 
and TGF-β1.
A 293T cell clone stably expressing GARP and TGF-β1 was transiently co-transfected with a CAGA-LUC reporter and 
a plasmid encoding a candidate protein, a negative control (PLD3) or ITGβ6. Luciferase activity was measured 24 
hours after transfection. In one control condition, recombinant human (rh) TGF-β1 (4 ng/mL) was added for 24 hours.
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Discussion
We attempted to identify Treg proteins implicated in TGF-β1 activation by IP followed by MS 
analysis.  This lead to the identification of a plethora of proteins (>2000), most of which are 
probable false positives. The list of potential candidates was narrowed down first  by eliminating 
proteins also identified in negative control IPs, and then using a criteria based on higher expression 
of the encoding genes in Tregs by comparison to Th cells. This left us with a list of 7 new potential 
GARP interactants overexpressed in Tregs. These candidates are currently  being assessed for their 
ability  to activate TGF-β1 in 293T cells stably expressing GARP. We already tested 4 candidates 
(LEPR, ITGAM, SNRK, and NLRP1), but none was able to activate TGF-β1. 
One of these four candidates is ITGAM  (integrin αM  or CD11b). We had considered this candidate 
particularly promising because other integrins were previously shown to activate TGF-β1 in cells 
such as dendritic cells or fibroblasts (Travis and Sheppard 2014). Our results in the 293T reporter 
assay were thus very disappointing. However, it  must be noted that integrins are heterodimers 
comprising an α  chain and a β chain. Therefore, the inability of ITGAM to activate TGF-β1 in 
transfected 293T cells may be due to the absence of the appropriate β chain. ITGAM is known to 
pair with ITGB2 (integrin β2 or CD18), forming the so-called Mac-1 heterodimeric integrin (Abram 
and Lowell 2009). We thus tested ITGAM  in the 293T cell reporter assay, this time co-transfecting 
ITGB2 with ITGAM. But we observed no TGF-β1 activation in this assay neither (data not shown). 
We are now left with only three candidates to test in the 293T reporter assay (TBC1D8, MAST4 
and NFATC1). All three show very striking overexpression in stimulated Treg cells by comparison 
to Th cells, and this is particularly  the case for TBC1D8. To date, the cloning of these candidates 
has remained challenging, but we hope to obtain vectors to test them very  soon. TBC1D8 is a 
member of the TBC1 domain containing family of proteins that have been described to function as 
GTPase-activating proteins (GAPs) for Rab GTPases.  A putative transmembrane domain was 
described in TBC1D8 sequence, suggesting that the protein could span cell membranes (Yonekura 
et al. 1999, Barr and Lambright 2010). However no experimental data are available to support this 
hypothesis. MAST4 is a member of the Microtubule-Associated serine/threonine-protein kinase 
(MAST) family of proteins, which are cytosolic kinases.  MAST4 protein function has not been 
well characterised.  Interestingly, it was shown to associate with SMAD1 suggesting a role in 
signalling induced by TGF-β family of proteins (Colland et al. 2004).  Finally, NFATC1 is a Ca2+-
regulated transcription factor from the Nuclear Factor of activated T-cells protein (NFAT) family 
that regulates transcription of numerous genes in T cells.  These three proteins constitute very 
interesting candidates by their expression profile and functions.
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Materials and Methods
Polyclonal cell sortings and short-term TCR stimulation
Polyclonal T cells were sorted as described previously (Gauthy et al. 2013). For protein 
identifications, polyclonal CD4+ (Th) and CD4+CD25+CD127- (Treg) cells were stimulated with 
anti-CD3 and anti-CD28 as previously (Stockis et al. 2009b).  For qPCR analysis polyclonal CD4+ 
and CD4+CD25+CD127- cells were incubated with Dynabeads® CD3/CD28 at a 1 cell to 1 bead 
ratio.  All stimulations were performed in IMDM supplemented with 10% human serum, L-
arginine, L-asparagine, L-glutamine, β-mercaptoethanol (5x10-5M), methyl-tryptophane (200 µM).
Immunoprecipitation and SDS-PAGE gel
Cell lysates were incubated with 40 µg/ml of MHG-6 anti-GARP antibody (in house antibody, 
(Cuende et al. manuscript submitted)), or isotype IgG2a control antibody.  Lysate-antibody  mixtures 
were incubated with Protein-G coated on magnetic beads (Dynabeads, Invitrogen). Beads were 
washed of unbound proteins using a Dynal magnet (Invitrogen). Immunoprecipitates were eluted 
from beads by boiling in Laemmli sample buffer supplemented with 5% β-mercaptoethanol 
(BioRad) and loaded on SDS-PAGE gel (4-12%, Bis-Tris Life Technologies).  
Silver staining and MS
SDS-PAGE gels were silver stained using SilverQuest kit (Life Technologies). Gels were 
fragmented and each piece was destained using the SilverQuest destainer reagents.  Proteins were 
submitted to in-gel trypsin digestion. Peptides were analysed by  capillary  LC-tandem mass 
spectrometry in a LTQ XL ion trap mass spectrometer (ThermoScientific) fitted with 
microelectrospray  probe. The data were analysed with the ProteomeDiscoverer software 
(ThermoScientific), and the proteins were identified with SEQUEST against a target-decoy 
nonredundant human protein database obtained from NCBI.  The False Discovery  Rate was below 
5%.
RT-qPCR SYBR 
Total RNA was extracted and reverse transcribed using the SuperScript Vilo cDNA synthesis kit 
(Life Technologies).  qPCRs were done using Takyon SYBR or Probe Mastermix Kit (Eurogentec) 
and amplifications were performed on ABI Prism 7300 or Step One Plus Real Time PCR Systems 
(Applied Biosystems)under standard conditions: 94°C for 3 min, 45 cycles of 94°C for 10 s, and 
60°C for 1 min. 
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qPCR primers for candidates used are, 5’ to 3’ Forward, Reverse :
LEPR: GTTCCTGGGCACAAGGACTTA, ACCACATGTCACTGATGCTGT ; 
NFATC1: AAAACTGACCGGGACCTGTG, GAACGGGGCTGGTTATCCTC ;
NLRP1: CTGCCTGCAAACTCATACGC, CCCTCAGTTCCTGCCTCATC; 
SNRK: CGGATCGAGACGCCATTGTA, CAGGATCCTTTCAGCCAGCA; 
PKN1: GGACAATGAGAGGCATGAGGT, AATGACAGGGTTGCGGAAGG ;
KIAA0746: ACTTTCTGGGAACCTTTCTGCT, ATGGTCTTGGAGGGGGATCG; 
ITPR2: TGGGGTTAGTGGATGACAGATG, TAGGGCACACCTTGAAAAGGC; 
ITPR3: AACAAGACCGACTACACGGG, CCCTCATTGCTGACAAGGGA;
NCOR1: GAAAATCCAGAAGACAGCGAAG, GTGTTTCCTCGAGAAGTAGCAT; 
UBR4: CGACCAGTGGAACTGTCCTG, ATGATTGGGCCAACGGCAAA; 
RAB5B: TGTCAAAGGGCAGTTCCATGA, AGACAAACGGACTGGGTGAG; 
PLD3: CTGCGTGACAACCATACCCA, ACACGGGCATATGGGATTCG; 
TRIB3: CCACGCGGAACGACGG, GTCATCCAACTCCAACCGCT; 
SLC23A2: GGGCTCGTCCTTCCAAGTTA, GCCCCCTACAAACATAGCAGT; 
SPG11: TGCCCGCATCCAACTGAAAT, GCCTTCAGCAGCAGTTGTTT; 
WDR7: TGGATGTGTCCGCTGTTCTG, TCAGAGGCAACCCCATTGTG ;
STEX: GTCACCATCACACGAGCCAA, CAGCTGATTCCAATGCTGGTT; 
MZF1: GAAGCTGGGGGCATCTTCTC, GTGGAGGTGAGGGCTTACAC; 
SATB1: CAGCAGGAAATGAAGCGTGC, GTAACAGCTCGCACAACCATC; 
KIAA0776: ACACATACAAGATGCCCCTGA, AATACTGAACGTACCACCTCG; 
EFR3A: AGTCGCTAGGTGGAAGTGGA, CGGTGTCCACAATGCTTTTTCT; 
SMCHD1: TCGGGGAATGGTATTTGGAGC, GTTTGCACACAGCAGAACGA; 
AGL: GCCCGGAGACTACTGCAAAG, GGAAGTCCTTTCCAAGGGGA; 
FLNB: CGCCTCACTGTTATGAGCCT, TCTTGCCTTTTGCGCCATTC; 
ARGHEF: AGGGGCATTCAGCAACAATG, TGTAGCGAGTGGGTCTGACT; 
SYNE1: AGCCAGATGGCTGAACATCA, TCCTCTGCGAGAGAGGACTG; 
MACF1: GAAAAGCCAGGATTCGGTGC, TTTCTTCTGAACCCGGTCCC; 
TBC1D8: CAGAACGTGCTTCGAGTCGT, GCTCCCAGTAACAGCTCATCA; 
MAST4: ATGGTGAGGCGGAGCAAGAA, TTCGGCTGGTGTGGAGTAAA; 
ITGAM: GTCCAGCTTCAGGGATCCAG, TAGTCGCACTGGTAGAGGCT.  
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For ACTB, B2M, EF1 and GARP taqman was performed. qPCRs primers used for GARP, EF1 are 
described (Stockis et al. 2009a).  qPCR primers, 5’ to 3’:
ACTB: Forward: ATTGCCGACAGGATGCAGAA, 
Reverse: GTCATACTCCTGCTTGCTGA, 
Probe: TCAAGATCATTGCTCCTCCTGAGC;
B2M: Forward: GGAGGCTATCCAGCGTACT,
Reverse: GACCAGTCCTTGCTGAAAGACA, 
Probe: GCTATGTGTCTGGGTTTCATCCATCCG.
Transient transfections
A 293T cell clone stably expressing GARP and TGF-β1 was transiently transfected with plasmids 
indicated in the figures using Lipofectamine 2000 (Life Technologies). Cells were analysed 24 
hours after transfection. Luciferase activity was measured with the Britelite Plus Reporter Gene 
Assay System (Perkin Elmer).
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Discussion and Perspectives
1. Two distinct approaches to identify GARP partners in 
human Tregs
Human Tregs but not other T cells activate TGF-β upon TCR stimulation. Although TGF-β 
production is an important immunosuppressive mechanism elaborated by  Tregs, the crucial step of 
TGF-β activation is not fully  understood.  Tregs, and not other Th cells, present latent TGF-β at 
their surface through binding to a transmembrane protein called GARP.  Surface presentation of 
latent TGF-β is required for TGF-β activation by Tregs: antibodies against the GARP/latent TGF-β 
complexes inhibit active TGF-β production by Tregs (Cuende et al. manuscript submitted). When 
transduced with GARP, Th cells acquire the ability to present latent TGF-β at  their cell surface but 
are still unable to activate TGF-β (Stockis et al. 2009b).  Therefore, we hypothesised that  one or 
more additional Treg protein(s) interact with the GARP/latent TGF-β complexes to allow TGF-β 
activation.   We decided to look for proteins that interact with GARP.  To achieve this, we used two 
different techniques.  First, we used the MYTH system in yeasts with GARP as a bait and a Treg 
cDNA library as preys. Second, we used an IP-GARP on Treg cell lysates followed by MS analysis.  
As for all Y2H systems, the MYTH system is suited to search for labile or weak interactions 
between two proteins.  In contrast, IP-MS approach is more adapted to identify strong interactions 
between two or more partners. These systems are thus complementary  and allow to cover a large 
panel of possible interactions.  Notably, the GARP partners that we identified with each method did 
not overlap. 
The MYTH system is designed to test interactions using transmembrane proteins as baits.  Since 
TGF-β activated by Tregs has paracrine actions on neighbouring T cells but is not soluble, we 
assume that TGF-β activation occurs close to the cell surface of Tregs and that it is likely that the 
crucial partner involved in TGF-β activation is also located at the cell membrane, together with the 
GARP/TGF-β complex. Therefore, the MYTH system, out of all Y2H systems, is the most adequate 
to identify this type of preys. 
The first prey cDNA library that we used was designed in such way that NUBG is fused at the N-
terminus of preys.  Screening of this library allowed for the identification of preys that are either 
membrane protein with a cytosolic N-terminal extremity (type II membrane proteins) or cytosolic 
proteins. It did therefore not cover all possible interacting proteins. This system led to the 
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identification of 14 potential GARP interactants. One of these, namely LAPTM4B, displays higher 
expression in Tregs than in Th cells at mRNA levels and could therefore be an interesting partner of 
GARP (see below).  We also constructed prey  cDNA libraries in which the NUBG was fused at the 
C-terminus of the preys.  This was expected to allow the identification of type I membrane proteins 
interacting with GARP.  However, screening of this library  lead to too many false positives, and we 
did not succeed in identifying any candidates with this approach (data not shown).
The main limitation of the MYTH approach is that it detects binary interactions between bait and 
prey.  However, the interaction between GARP and a partner in Tregs could necessitate the presence 
of TGF-β associated to GARP. We also tried to improve the efficiency of the screening by 
expressing human TGF-β in yeasts, postulating that interesting GARP partners could bind GARP 
better in the presence of TGF-β.  We succeeded in expressing human TGF-β in yeast, and could 
show that it was properly  processed into latent TGF-β (i.e. cleaved into LAP and mature TGF-β). 
Unfortunately, expression of TGF-β was toxic in yeast, leading to slow growth and inefficient 
library transformation.  Thus we could not efficiently screen prey  cDNA library screen in these 
conditions.  
The alternative IP-MS approach has the advantage to detect interactions with endogenous GARP in 
human Tregs i.e. unmodified.  However the technique is limited by the strength of the interactions 
between GARP and its partner(s), and by the affinity of the antibody.  The anti-GARP antibody 
used for IP has been derived in house (Cuende et al. manuscript submitted).  It binds both free 
GARP and GARP bound to latent TGF-β.  This antibody is not a blocking antibody: it does not 
inhibit TGF-β activation by  Tregs, and therefore is not expected to disrupt interactions with proteins 
essential for TGF-β activation.  The IP-MS approach allowed the identification of 34 potential 
GARP partners with 7 of them displaying higher expression in Tregs compared to Th cells (see 
below).  
Since cell-cell contact is required to allow TGF-β signalling in a Treg target, one possibility is that 
the essential partner leading to TGF-β activation is presented by  the target cell and not by the Treg 
itself.  Such activation could be termed «trans» activation, by contrast to «cis» activation achieved 
by a protein on the Treg cell itself (Figure 1).  The group of T. Springer, described a «trans» 
activation of TGF-β bound to GARP triggered by integrins β6 and β8 expressed on cells that do not 
express GARP (Wang et al. 2012).  This was done in transfected 293T cells expressing GARP and 
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TGF-β mixed in culture with 293T cells transfected with ITGβ6 or ITGβ8 and co-cultured with a 
reporter cell line expressing luciferase in response to TGF-β signals. In this experiment, the authors 
observed indeed luciferase activity indicating that integrins can lead to activation of latent TGF-β 
presented by GARP in trans.  The MYTH system is unable to detect «trans» interactants because 
reporting of the interaction require bait and prey  to be located in the same yeast. The IP-MS 
approach, however, could lead to the identification of such partners, but will require a strong 
interaction between the partners to be conserved along the lysis and washing processes.  
Figure 1. Representation of «cis» and «trans» models for TGF-β activation by Tregs.
Latent TGF-β1 is presented at the surface of Tregs through binding to GARP.  Activation may occur in «cis» : Treg 
proteins may interact with GARP/TGF-β complex in the Treg itself, leading to TGF-β activation. Active TGF-β can 
then act in an autocrine or paracrine manner. Alternatively, TGF-β activation may occur in «trans» meaning that the 
protein required for TGF-β activation is located on the surface of the cell facing the Treg (another cell type or a Treg).  
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A class of proteins that represents interesting GARP/TGF-β potential partners are secreted proteins. 
They  could be involved in latent TGF-β activation or in shedding of GARP/TGF-β complexes. 
However, secreted proteins cannot be identified in the MYTH approach.  A different Y2H system 
specifically designed for the identification of extracellular proteins does exist: the SCINEX-P 
system, detecting interactions in the ER (Urech et al. 2003).  We could have used this technique to 
identify GARP/TGF-β partners.  Yet, secreted proteins could have been identified with the IP-MS 
system if they were retained at the cell membrane via the interaction with GARP.  However, none of 
the candidates identified by IP-MS were extracellular proteins. To identify secreted proteins 
interacting with GARP, we also attempted to fuse preys with a transmembrane domain to retain the 
extracellular proteins at the cell membrane.  We first assayed this system by fusing TGF-β with a 
transmembrane domain. However, we did not succeed in expressing TGF-β in fusion with 
transmembrane domain in yeast and did not further used this approach.  
Altogether, our two approaches to identify  GARP partners led to identification of a few interesting 
candidates that include membrane and cytosolic proteins.  Unfortunately, we haven’t succeeded yet 
in showing that any of them is implicated in the TGF-β activation process. Below we discuss further 
these interesting candidates.
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2. Seven candidates identified by IP-MS
The IP-MS approach identified a short-list of 7 potential GARP partners with higher mRNA 
expression in Tregs than in Th. Their interaction with GARP will have to be confirmed by an 
alternative technique, using for example the Gaussia luciferase complementation assay  that we 
successfully  used to confirm interaction with LAPTM4B.  But instead of first verifying interaction 
for these candidates, we chose to start  by screening which ones could be implicated in TGF-β 
activation, using a reporter assay  in 293T cells. Four candidates, NLRP1, LEPR, ITGAM, and 
SNRK, did not induce TGF-β activation in this assay. Three candidates, namely TBC1D8, MAST4, 
and NFATC1 have not been tested yet in this assay, and are thus still potentially interesting 
candidates.
TBC1D8, or TBC1 domain family member 8, is a 1140 amino acid protein, member of the TBC1 
domain-containing family of proteins. This family  includes proteins containing a Tre-2/Bub2/Cdc16 
(TBC) domain. This domain is a conserved protein motif that  consists of approximately  200 amino 
acids and is thought to function as a Rab-GAP domain (Barr and Lambright 2010, Fukuda 2011). 
More than 40 distinct TBC domain-containing proteins have been identified and over 60 Rab 
proteins are found in humans.  Not all Rab proteins have been studied but the current  view is that 
Rab proteins are involved in vesicle trafficking processes (Barr and Lambright 2010).  The GAP 
activity and specificity  of most TBC proteins have never been determined (Fukuda 2011).  TBC1D8 
gene is highly conserved and found in many species including human, chimpanzee, rhesus monkey, 
mouse, rat, chicken and zebrafish. No function for this gene has been identified in the immune 
system. However, it was suggested to be important for endothelial cell proliferation and 
angiogenesis, and was therefore initially called Vascular Rab-GAP/TBC1 domain containing 
protein (VRP) (Yonekura et al. 1999). It was proposed that TBC1D8 contains a putative 
transmembrane domain, but this was never confirmed experimentally (Yonekura et al. 1999).  The 
topology and subcellular location of TBC1D8 remain to be studied.
MAST4, or Microtubule-associated Serine/Threonine kinase 4, is a member of the MAST family of 
cytosolic kinases that comprises 5 members: MAST 1 to 4, and the MAST-like protein. The 
functions of these proteins have not been well characterised. Interestingly though, a Y2H system 
identified MAST4 as a partner for SMAD1, suggesting a role for this protein in signalling pathway 
with members of the TGF-β family (Colland et al. 2004).  
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NFATC1, or Nuclear Factor of activated T-cells cytoplasmic 1 protein, is a Ca2+-regulated 
transcription factor from the NFAT family.   NFAT transcription factors regulate several processes in 
vertebrates, including the development and function of the innate and adaptive immune system 
(Vihma et al. 2008, Zanoni and Granucci 2012).  NFAT proteins are located in the cytosol in an 
inactive phosphorylated state. Upon dephosphorylation by calcineurin, NFAT proteins are activated 
and translocate to the nucleus where they  associate with other factors to modulate gene 
transcription.  In T cells, NFAT induce and repress the transcription of many genes, resulting in 
modulation of T cell activation, proliferation and differentiation (Zanoni and Granucci 2012). 
These three candidates indicate a potential role for GARP in signalling pathways. The possibility 
that GARP induces intracellular signals has not been studied yet but cannot be excluded. The 
intracellular portion of GARP is very  small (15 amino acids), suggesting that, signalling through 
GARP would require the recruitment of adaptor molecules.  We tested potential signalling through 
GARP by  comparing Th cells transduced or not with GARP, and exposed or not to latent TGF-β, 
and then analysed p-JNK, p-ERK and p-p38 by  WB.  No signs of differential intracellular signalling 
due to GARP expression was detected using antibodies against theses molecules. Of course, 
signalling through GARP could occur through many other pathways. If interaction with TBC1D8, 
MAST4 or NFATC1 are confirmed, this line of research could be further explored.
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3. LAPTM4B, a candidate identified by MYTH
3.1. Regulation of LAPTM4B expression
Using the MYTH approach with GARP as a bait and a Treg cDNA library as prey, we identified a 
new partner of GARP called LAPTM4B.  Transcription of the LAPTM4B gene yields at least two 
mRNA variants in human Tregs: Va and Vb.  Expression of Va and Vb is higher in Tregs than in Th 
clones after TCR stimulation.  We also examined Va and Vb expression in human tissues (data not 
shown). We observed that while Va is ubiquitously expressed, Vb is only  detected at high levels in 
stimulated Treg clones or polyclonal Tregs.  Low level expression of Vb was also detected in some 
tissues including muscle and bone marrow.  
How the LAPTM4B gene is regulated at a transcriptional level has not been extensively studied. 
The group of Zhang investigated this question in human breast cancer cells (Zhang et al. 2013). 
They  revealed that the first exon of LAPTM4B contains conserved binding site for cAMP 
responsive element binding protein-1 (CREB1), and showed using electrophoretic mobility shift 
assay (EMSA) that CREB1 directly  binds to this LAPTM4B regulatory region.  This regulatory 
mechanism could also function in Tregs since CREB transcription factors were shown to control 
gene transcription in these cells, such as Foxp3 transcription in murine Tregs (Kim and Leonard 
2007, Ogawa et al. 2014). 
Very  interestingly, overexpression of LAPTM4B in human or mouse Tregs was observed in several 
published expression microarray data sets (Herman et al. 2004, Williams and Rudensky 2007). 
Moreover, transduction of non-Treg cells with FOXP3 leads to LAPTM4B overexpression 
(Ocklenburg et al. 2006). Together, these data suggest that gene LAPTM4B might be 
transcriptionally regulated by FOXP3.
LAPTM4B variants encode different protein isoforms with truncated N-terminal portions, depending 
on the start codon used to initiate translation. Unfortunately, we lacked antibodies against the 
LAPTM4B isoforms expressed in Tregs to study protein expression.
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3.2. Roles of LAPTM4B in human Tregs
We showed for the first time a function of LAPTM4B in the immune system.  LAPTM4B interacts 
with GARP.  GARP and LAPTM4B appear to associate directly, as suggested by the fact that they 
interact when co-expressed in yeast.  However, one cannot formally exclude that the interaction 
between the two partners requires an additional protein that is present  in mammalian cells and for 
which a homolog exists in yeast. Which or whether both isoforms LAPTM4Biso24 and 
LAPTM4Biso20 interact with GARP is not yet elucidated. In the Gaussia luciferase complementation 
assay, co-transfection of GARP with a vector encoding LAPTM4Biso24 and LAPTM4Biso20 leads to 
similar luciferase activity compared to a vector encoding LAPTM4Biso20 only, indicating that the N-
terminus of LAPTM4Biso24 is not required for the interaction with GARP. To define which 
isoform(s) interact(s) with GARP, we could perform PCA using LAPTM4B constructs in which in 
frame ATGs are mutated, so that vectors would code for only one of the two LAPTM4B isoforms.
Overexpression analysis in 293T cells, and knock-down approach in Tregs revealed that LAPTM4B 
decreases GARP surface levels, cleavage of pro-TGF-β precursor, and therefore latent TGF-β 
secretion and surface presentation.  Again, which isoform of LAPTM4B plays these roles in human 
Tregs is not elucidated.  Indeed, all isoforms were silenced in Tregs with siLAPTM4B.
Altogether, we concluded that LAPTM4B is a negative regulator of TGF-β production in Tregs, 
acting through both GARP-dependent and GARP-independent ways.  
3.3 Other described functions of LAPTM4B, and LAPTM family members 
Studies of LAPTM4B functions were so far limited to the analysis of isoform LAPTM4Biso35, which 
does not appear to be present in human Tregs. Several studies revealed that high expression of 
LAPTM4Biso35 in human cancers is associated to poor prognosis (Zhou et al. 2007, Yang et al. 
2008, Zhou et al. 2008, Yang et al. 2010, Yang et al. 2010, Yin et al. 2011, Kang et al. 2012, Zhang 
et al. 2012, Tang et al. 2014, Zhang et al. 2014).  High LAPTM4Biso35 expression in cancer tissues 
was demonstrated by immunohistochemistry  using antibodies against the N-terminus of the protein. 
These antibodies do not bind LAPTM4Biso24 and LAPTM4Biso20,  which lack the N-terminus found 
in LAPTM4Biso35.
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In cancer cells LAPTM4Biso35 isoform was shown to increase cell proliferation, migration, and 
invasion in vitro, and to increase the metastatic potential of tumour cells in vivo (Liu et al. 2009, 
Yang et al. 2010). LAPTM4B gene amplification was shown to induce resistance to cancer cell 
chemotherapy and recurrence of breast cancer (Li et al. 2010).  
In addition to LAPTM4B, the LAPTM family comprises two other members: LAPTM4A and 
LAPTM5.  Analysis of the subcellular localisation of LAPTM4A and 5 proteins indicate that they 
are present in late endosomes and lysosomes whereas, LAPTM4B was found present at the cell 
membrane (Milkereit and Rotin 2011). We analysed LAPTM4B subcellular localisation in 
transiently  transfected COS7 cells by  immunofluorescence. As shown in Figure 2, LAPTM4B 
staining (red) co-localises with the median Golgi marker GM-130 (green). This contrasts with the 
results obtained by Milkereit and Rotin, although we cannot exclude the presence of LAPTM4B on 
the membrane in addition to the Golgi on the basis of our results.
Figure 2: Subcellular localisation of LAPTM4B. 
COS7 cells were transfected with a vector coding for LAPTM4B in frame with a MYC Tag. 24 hours after transfection, 
cells were stained with anti-MYC (red) and anti-GM-130 (green) antibodies. Two transfected cells and their GM-130 
staining are indicated by arrowheads.  
GM-130LAPTM4B (MYC)
Staining Overlay
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LAPTM proteins share conserved PY motifs in their C-terminus, which bind to WW domains in 
proteins with whom they associate. LAPTM4B and LAPTM5 were both shown to interact with E3 
ubiquitin ligase Nedd4 (Pak et al. 2006, Milkereit and Rotin 2011). Interaction of LAPTM5 with 
Nedd4 was found to be crucial for its transport from the Golgi to the lysosomes, but this was not the 
case for LAPTM4B (Pak et al. 2006, Milkereit and Rotin 2011). Very interestingly, in a Y2H 
screen, LAPTM5 was also found to interact with SMURF2, an ubiquitin ligase for SMADs known 
to downregulate TGF-β signals (Colland et al. 2004, Itoh and ten Dijke 2007). We could thus 
speculate that several LAPTM proteins control TGF-β signalling pathway in T cells.  LAPTM5 was 
also shown to interact  with and regulate surface levels of T cell and B cell receptors (Ouchida et al. 
2008, Ouchida et al. 2010). This function require PY motifs in LAPTM5, and appear to occur 
through targeting of the immune receptor components to the lysosomes. We could speculate that 
LAPTM4B also regulates GARP levels by promoting its lysosomal degradation. Mutating PY 
motifs in LAPTM4B could help determine whether they are important for association with GARP 
and regulating of its surface levels. However, our analyses as well as observations from others 
(Milkereit and Rotin 2011) did not reveal a lysosomal localisation of LAPTM4B, suggesting that 
other mechanisms are probably involved. We analysed by immunofluorescence whether the 
subcellular location of GARP was modified in the presence of LAPTM4B. In transfected COS7 
cells, we observed that GARP and LAPTM4B co-localise mostly  in the median Golgi. We assessed 
whether GARP subcellular location was modified by looking at the distribution of GARP staining 
in individual cells.  As shown in Figure 3, the localisation of GARP was not modified in the 
presence of LAPTM4B.
3.4. LAPTM4B in Treg suppressive function
Our initial aim was to identify Treg proteins involved in TGF-β1 activation, one mechanism of the 
Treg immunosuppressive function. However, LAPTM4B expression did not induce TGF-β1 
activation in a 293T clone stably expressing GARP and TGF-β1.  In the same line, siLAPTM4B did 
not modify  TGF-β1 activation in human Tregs. We did not test whether LAPTM4B silencing 
increases the Treg immunosuppressive function, but this could be of interest. By inducing  general 
decrease in TGF-β1 production, LAPTM4B could dampen the Treg suppressive activity.  Moreover, 
Laptm5 KO in murine T cells led to an increase in TCR surface levels compared to their WT 
counterparts (Ouchida et al. 2008). Further studies will be needed to evaluate the importance of 
LAPTM4B in Treg function.
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Figure 3: Subcellular localisation of GARP in the presence or absence of LAPTM4B.
COS7 cells were transiently transfected with GARP alone or in combination with LAPTM4B (MYC tagged). 24 hours 
after transfection, cells were stained with anti-GARP and anti-MYC antibodies. Localisation of GARP was assessed in 
60 cells co-transfected by GARP and LAPTM4B and in 38 cells transfected with GARP alone.   Proportion of cells 
showing GARP accumulation in the Median Golgi is represented by grey bar while proportion of cells showing a 
distribution of GARP all across the secretory pathway are annotated in black.
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4.  TGF-β activators in Tregs
So far, none of the tested candidates isolated by  IP-MS or by  Y2H appears to contribute to 
activation of TGF-β.  To address this question, we transfected each candidate in a 293T cell clone 
stably  expressing GARP and TGF-β, together with a luciferase reporter activated upon TGF-β 
signals.  This 293T cell clone presents latent TGF-β at the cell surface, but does not activate the 
cytokine spontaneously.  Transfection of known activators of TGF-β, such as ITGβ6 or ITGβ8, 
induces TGF-β activation in this clone.  It  is therefore a very sensitive system, which could be 
implemented for large screenings.  Sara Lecomte in our group will further exploit this system to 
perform a high-throughput screening for TGF-β activators in human Tregs.  She will co-transfect 
pools of a Treg cDNA library in the 293T cell clone expressing GARP and TGF-β, together with the 
TGF-β luciferase reporter plasmid. The objective of this project will be to identify proteins involved 
in TGF-β activation in Tregs. In contrast to our approach, the candidates will not be selected on the 
basis of an interaction with GARP. 
Very  recently, Edwards and co-workers suggested a role for the αvβ8 integrin in TGF-β activation 
from GARP/TGF-β complexes in mouse Tregs (Edwards et al. 2014).  By RT-qPCR, they  revealed 
that the Itgb8 is expressed at substantially higher levels in Tregs than in non-Treg CD4+ T cells. 
They  showed that  WT Tregs, but not Itgb8 KO Tregs, promote the in vitro differentiation of naïve 
T cells into Th17 cells or iTregs, two processes known to rely on TGF-β (Edwards et al. 2014). 
Moreover, co-culture of Garp-/-/Itgb8+/+ Tregs with Garp+/+/Itgb8-/- Tregs lead to Th17 
differentiation of naïve T cells, indicating that Itgb8 can activate latent TGF-β presented by GARP 
in trans. However, the suppressive activity  of Itgb8-/- Tregs in vitro and in vivo was not different 
from that of their WT counterparts (Edwards et al. 2014).  This confirmed their previous 
observation that,  the suppressive activity of Tregs in the absence of GARP remains unaltered 
although TGF-β activation is impaired (Edwards et al. 2014).  Altogether, these results indicate that 
the release of active TGF-β from GARP/TGF-β complexes by mouse Tregs is mediated by the αvβ8 
integrin, and that the activation process can occur in «trans».  In our group, Julie Stockis 
investigated the possible implication of the αvβ8 integrin in TGF-β activation by human Tregs as 
well.  The study of ITGB8 mRNA expression in human Treg and Th cells revealed that its 
expression is higher in Tregs compared to Th cells upon TCR stimulation (Stockis et al. 
unpublished data). Theses results are in line with the observations made in murine Tregs by the 
group of Shevach (Edwards et al. 2014).  Overexpressing ITGB8 integrin in our 293T cell clones 
Discussion and Perspectives________________________________________________________________________________________________
123
expressing GARP/TGF-β leads to TGF-β activation, as reported with the CAGA-LUC reporter. 
However, activation is inferior to that obtained by overexpressing ITGB6.  Up to now, we have not 
been able to show that anti-integrin β8 blocking antibodies inhibits  TGF-β activation by  human 
Tregs.  We are trying to derive our own anti-integrin β8 antibodies to further explore this analysis. 
This will be part of the project of Sara Lecomte in our laboratory. She will also try  to derive 
antibodies targeting proteins that she will identify  by screening the Treg cDNA library in the TGF-
β-reporter assay in 293T cells.  She may also attempt to obtain antibodies against TBC1D8, the only 
candidate protein identified by IP-MS which could be localised at  the cell membrane. If any of 
these antibodies block TGF-β activation by Tregs in vitro, they  will be tested for their ability  to 
inhibit the immune suppressive function of Tregs in vivo. The ultimate objective would consist in 
obtaining new therapeutic tools to boost immune responses in cancer or chronic infections.  
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